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Zusammenfassung i
Zusammenfassung
Die Hyperurikämie (HU), gekennzeichnet durch einen erhöhten Harnsäurewert im Blut
(Serum Harnsäure ≥7.0 mg/dl bei Männern und ≥6.0 mg/dl bei Frauen), tritt häufig bei
Patienten mit einer chronischen Niereninsuffizienz (CNI) / Niereninsuffizienz im Endstadium
(ESKD) auf, und ist mit einer Vielzahl an Erkrankungen assoziiert. Jedoch ist die Kausalität
der löslichen Harnsäure bei diesen Krankheiten umstritten. Unter bestimmten Bedingungen
kann die lösliche Harnsäure zu Mononatriumurat (MSU)-Kristallen im Gelenk ausfallen und
eine akute Entzündungsreaktion auslösen, bekannt als Gichtarthritis. Während eine
persistierende HU stark mit der Gichtarthritis verbunden ist, kann eine rapide Reduzierung
der HU mittels Harnsäure-senkender Therapie auch zu einem akuten Gichtanfall führen.
Außerdem ist die Prävalenz akuter Gichtanfälle bei Patienten mit CNI viel niedriger als
erwartet trotz persistierender HU. Das Ziel dieser Doktorarbeit war, zu untersuchen ob die
lösliche Harnsäure eine immunmodulatorische Wirkung auf die MSU-Kristall-induzierte
Entzündungsreaktion hat.
Um dies zu untersuchen, haben wir ein Tiermodell basierend auf dem Urat-Transporter Glut9
etabliert. Dazu wurden sechs Wochen alte Alb-creERT2/Glut9lox/lox Mäuse oder Glut9lox/lox
Kontrollmäuse mit Tamoxifen injiziert, um die Glut9-Expression in Hepatozyten zu
deaktivieren. Den transgenen Tieren wurde anschließend eine fettreiche- oder Standarddiät
mit dem Purin Inosin verabreicht. Nach 22 Tagen entwickelten alle Alb-creERT2/Glut9lox/lox
Mäuse nach Gabe der Inosin-angereicherten Diäten eine deutliche HU (Serum-Harnsäure:
10 – 15 mg/dl). Jedoch nur Alb-creERT2/Glut9lox/lox Mäuse entwickelten eine HU und CKD
(Serum-Harnstoff: 110 mg/dl; Serum-Kreatinin: 2,0 mg/dl). Um eine akute Gichtarthritis
nachzuahmen, injizierten wir diese Mäuse mit MSU-Kristallen in einen bereits vorhandenen
Luftbeutel auf dem Rücken. Interessanterweise fanden wir heraus, dass die HU die
Leukozytenrekrutierung nach MSU-Kristall-induzierter Entzündung in dem Luftbeutel
beeinträchtigte. Intravitalmikroskopie des M. Cremaster zeigte, dass die HU speziell die
Rollgeschwindigkeit der Leukozyten erhöhte, jedoch die Adhäsion und Rekrutierung ins
Gewebe sowie die Leukozyten-bedingte Gewebeentzündung reduzierte. Die CKD-vermittelte
Abschwächung der durch MSU-Kristalle-induzierte Entzündung war nach Behandlung von
HU-Mäusen mit Rasburicase, einer rekombinanten Urat-Oxidase, welche die lösliche
Harnsäure in das wasserlösliche Allantoin abbauen kann, vollständig reversibel.
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In Neutrophilen, die aus dem Blut gesunder Individuen isoliert worden waren, verringerte die
lösliche Harnsäure die β2 Integrin-Expression von LFA-1 und Mac-1, sowie die β2 Integrin-
Aktivierung (die offene Konformation mit hoher Affinität), wodurch die lösliche Harnsäure
die Migration der Neutrophilen in Richtung der Chemoattraktionsfaktoren IL-8, IL-1β und
fMLP beeinträchtigte. Eine beeinträchtigte Migrationsfähigkeit wurde auch bei Neutrophilen
von Patienten im CKD-Stadium G2-4 und G5D beobachtet. Ich konnte zudem zeigen, dass
Seren von hyperurikämen ESKD-Patienten die Migrationsfähigkeit von Neutrophilen im
Vergleich zu Seren von gesunden Individuen stark vermindert. Dieser Effekt war nach
Vorbehandlung der Seren mit Rasburicase reversibel. Diese Daten verdeutlichten, dass die
HU zu einer Beeinträchtigung der Migrationsfähigkeit von Neutrophilen von ESKD-
Patienten beiträgt. Darüber hinaus schwächte die lösliche Harnsäure signifikant die durch
LPS und MSU-Kristall-induzierte Toll-like- und TNF-α-Rezeptor-vermittelte Monozyten-
Aktivierung, was zu einer reduzierten Freisetzung pro-inflammatorischer Zytokine führte.
Dieser Prozess war stark von der intrazellulären Aufnahme der löslichen Harnsäure mittels
des Urat Transporters SLC2A9 (GLUT9) in den Monozyten abhängig. Wir haben auch
herausgefunden, dass die HU die Freisetzung von MSU-Kristall-induzierten Neutrophilen-
extrazellulären DNA und toxischen Mediatoren (NETs) nicht direkt beeinflusst, stattdessen
indirekt die NETs-Bildung durch freigesetzte pro-entzündliche, lösliche Mediatoren
beeinflusste.
Zusammenfassend zeigen die Ergebnisse dieser Arbeit, dass die HU die sterile Entzündung
unterdrückt, indem sie die Migration von Neutrophilen ins Gewebe und die durch den pattern
recognition Rezeptor gesteuerte Monozyten-Aktivierung moduliert. Diese molekularen
Mechanismen liefern eine mögliche Erklärung für die bislang ungeklärten klinischen
Phänomene von akuten Gichtanfällen kurz nach rascher Korrektur der HU sowie die
unerwartet niedrige Prävalenz von Gichtarthritis bei ESKD-Patienten trotz persistierender
HU.
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Summary
Hyperuricemia (HU), an excess of uric acid (UA) in the blood (serum UA ≥7.0 mg/dl for
men and ≥6.0 mg/dl for women), is common in patients with chronic kidney disease
(CKD)/end-stage kidney disease (ESKD) and associated with various diseases. However, the
causality of soluble uric acid (sUA) remains controversial in these diseases. Under certain
conditions, UA can precipitate into monosodium urate (MSU) crystals in joints, inducing an
acute inflammatory response, known as acute gouty arthritis. While persistent HU is strongly
associated with gouty arthritis, a rapid correction of HU with urate lowering therapy (ULT)
can elicit acute gouty arthritis. In addition, only a minority of patients with advanced CKD-
related HU experiences gouty arthritis. The aim of this thesis was to investigate whether sUA
might exert immunomodulatory effects during sterile inflammation induced by MSU crystals.
To investigate this, we established an animal model based on the urate transporter Glut9. Six
weeks old Alb-creERT2/Glut9lox/lox or Glut9lox/lox control mice were injected with tamoxifen
to turn off Glut9 expression in hepatocytes and placed on a chow or high-fat diet enriched
with the purine inosine. After 22 days, all Alb-creERT2/Glut9lox/lox mice fed with inosine
developed HU (serum UA: 10-15mg/dl). Only Alb-creERT2/Glut9lox/lox mice on high fat diet
with inosine developed HU+CKD (serum BUN: 110 mg/dl, creatinine: 2.0 mg/dl). To mimic
acute gouty arthritis, those mice were injected with MSU crystals into a pre-existed air pouch.
Interestingly, HU impaired leukocyte recruitment in response to MSU crystal-induced
inflammation. Intravital microscopy of the cremaster muscle revealed that HU specifically
increased leukocyte rolling velocity but reduced leukocyte adhesion, extravasation, and
leukocyte-related tissue inflammation. The CKD-mediated attenuation of MSU crystal-
induced inflammation was fully reversible by treating HU mice with rasburicase, a
recombinant urate oxidase that can degrade UA into the water-soluble allantoin.
In blood neutrophils isolated from healthy individuals, sUA diminished β2 integrin
expression (LFA-1 and MAC-1) and activation (the open conformation with high affinity),
hence sUA impaired neutrophil migration towards the chemoattractants IL-8, IL-1β and
fMLP. An impaired migratory capability was also observed in neutrophils from CKD stage
G2-4 or G5D patients. Sera from hyperuricemic ESKD patients impaired the migratory
capability of neutrophils compared to sera from healthy individuals. This effect was
reversible after pre-treating sera with rasburicase. These further indicated that HU contributes
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to the impaired ability of neutrophils from ESKD patients to migrate. Moreover, sUA
attenuated LPS and MSU crystal-induced Toll-like and TNF-α receptor-mediated monocyte
activation, resulting in less pro-inflammatory cytokines release, a process strongly dependent
on the intracellular uptake of sUA via the urate transporter SLC2A9/GLUT9. In addition, HU
did not directly affect MSU crystal-induced neutrophil extracellular traps (NETs) formation,
but instead indirectly affected NET formation via monocyte-derived soluble mediators.
In summary, the results of this thesis indicate that HU suppresses sterile inflammation by
modulating neutrophil migration and pattern recognition receptor-driven monocyte activation.
This process provides a molecular explanation for the previously unexplained clinical
phenomena of gouty arthritis flares early after rapidly correcting HU as well as the
unexpectedly low prevalence of gouty arthritis in ESKD patients despite persistent HU.
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1 Introduction
1.1 Chronic kidney disease
1.1.1 Classification of chronic kidney disease
Chronic kidney disease (CKD), formerly known as chronic kidney injury is a global public
health problem affecting almost 10% of the world population. In Latin America, Europe, East
Asia and the Middle East, the prevalence of CKD increases even up to approximately 12%.
In contrast, South Asia and Sub-Saharan Africa report the lowest prevalence with 7% and 8%,
respectively1. The incident of CKD also varies due to age, ethnicity, economic status and
other factors2.
CKD is a progressive loss of kidney function, which is characterized by a persistent
abnormality in the function of the kidney [glomerular filtration rate (GFR) below 60 ml/min/
1.73 m2] over a period of three months3. GFR and albuminuria are well-established indicators
for CKD because the GFR is used for evaluating kidney excretory function and albuminuria
for kidney permeability. The different severity stages of CKD based on GFR and albuminuria
are classified in the kidney disease improving global outcomes (KDIGO) guidelines, as
shown in Figure 1.
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G2 Mildly decreased 60-89
G3a Mildly to moderatelydecreased 45-59
G3b Moderately to severelydecreased 30-44
G4 Severely decreased 15-29
G5 Kidney failure <15
Figure 1: The KDIGO classification of CKD. Summary of KDIGO 2012 CKD Guideline: Behind
the scenes, need for guidance, and a framework for moving forward.4 Reproduced with permission.
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1.1.2 Risk factors of CKD
Modern lifestyles, such as unhealthy diets, lack of exercise, smoking and drinking, are direct
causes of obesity, diabetes, and elevated hypertension, which in turn arises the risk for
developing CKD. Hypertension, diabetes and obesity have become the main causes of CKD.
In addition, in developing countries infections and heavy metal or pesticides exposures play a
big role in contributing to CKD.
Hypertension
Hypertension is closely related to various causes of CKD. As kidney function declines, blood
pressure tends to increase, which in turn impairs kidney function5. In 2000, more than 25% of
the adult population have high blood pressure, which is expected to increase to 60% by 20256.
Blood pressure severity is directly related to the risk of end-stage kidney disease (ESKD) in
both men and women7. One study including 3612 adults with CKD shows that the prevalence
of hypertension was 86%, while only 29% in the general population8.
Diabetes
Regardless of income, diabetes is a major cause of CKD all over the world. Among all types
of CKD, diabetic nephropathy accounts for 30-50%. In most developed countries, diabetes is
the leading cause of ESKD, and the prevalence of ESKD in the world has increased
significantly. Notably, 285 million (about 6.4%) of adults worldwide have diabetes, and the
global prevalence of diabetes is expected to reach 642 million by 2040. Therefore, improving
outcomes for patients with diabetes and CKD have critical health and economic implication9.
Obesity
Obesity, the largest epidemic in the near history carries a markedly increased risk for CKD.
Between 1978 and 2013, the proportion of overweight and obese adults (body mass index
(BMI) above 25kg/m2) worldwide increased from 28.8% to 36.9% among men, and from
29.8% to 38.0% among women10. In particular, the obesity rate in the Middle East and North
America is more than 30%2. Meanwhile, patients with ESKD in North America who
underwent dialysis had a much higher incidence of obesity than the general population11, and
a survey of the European populations found that high levels of BMI were among the most
dangerous factors in new-onset long-term kidney disease12. However, it is still not clear
whether obesity affects the development of early kidney disease.
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Obesity not only aggravates the risk of CKD directly but also influences other chronic
diseases such as diabetes and high blood pressure, which indirectly impair CKD13. Especially,
obesity is known to be a frequent cause of type 2 diabetes and diabetic kidney disease14. In
obese people with a high salt and protein intake, the oxidative stress level, kidney damage
and inhibited glomerular auto-regulation will increase15. Changes in renal hemodynamics and
adipose tissue-derived adipokines play a key role in obesity-associated nephropathy16.
Other factors
Acute kidney injury (AKI) episodes are also a risk factor for CKD. If AKI is not treated
promptly and effectively, it can cause damage to the kidneys by irreversible nephron loss,
thus exacerbating the development of CKD2. Men are more likely to develop CKD than
women, and have a higher chance of ESKD1. Infectious diseases, e.g. hepatitis B and
hepatitis C infection affect about 500 million population in the world, and they are associated
with severe kidney disease17. Certain populations, such as Australian natives, African
Americans, South Asian and Pacific Islanders, are at higher risk than others, which implies
the importance for genetic factors in increasing the risk of developing CKD18. Studies have
shown that variants in the APOL1 gene are almost exclusively present in people of West
African origin and that these variants are strongly linked to increased risk of human
immunodeficiency virus-associated nephropathy19,20. Environmental factors, heavy metals
and organic compounds in the soil, such as pesticides, can also cause kidney damage21. Air
pollution with elevated levels of fine particles at aerodynamic diameter above 2.5 μm (PM2.5)
are significantly associated with risk of incident CKD, eGFR decline, and ESKD22.
1.1.3 Complications of CKD
The kidney is related to a variety of critical processes of body homeostasis. The outcomes of
CKD are complex and related with other diseases. Cardiovascular disease, anemia,
hypertension, mineral bone disorder, infections, volume overload, electrolyte, and acid-base
abnormalities are well defined CKD complications23.
Cardiovascular disease
Cardiovascular disease is a class of diseases that pertain to the blood vessels of the heart, e.g.
hypertension, coronary artery disease, heart attack, and stroke, are leading causes of death
and closely interrelated with CKD24. In CKD, studies have shown the prevalence of vascular
calcification ranges from 47%-92%25. It is estimated that patients with a GFR below
60ml/min/1.73 m2 have 57% higher mortality and 33% higher risk of a non-fatal myocardial
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infarction than people without CKD26. When it comes to micro-albuminuria, the mortality
and risk of non-fatal myocardial infarction are even higher, 63% and 48%, respectively27. A
large analysis of 83 studies found an inverse linear association between GFR and risk of
stroke, the risk increased by 7% for every 10ml/min/1.73 m2 decrease in GFR28.
Anemia
Anemia is one of the common characteristics of CKD and the incidence increases as GFR
declines. The reduction of renal erythropoietin reduced lifespan of red blood cells, iron
deficiency and repetitive blood loss contribute to anemia in CKD29. The overall prevalence of
CKD-related anemia is around 50%30. The severity of CKD is also associated with the
prevalence of anemia, 25% with CKD stage 1, 50% with CKD stage 2, 3 and 4, and 75% of
CKD patients starting dialysis suffer from anemia30.
CKD Mineral and Bone Disorders
CKD mineral and bone disease is another common complication of CKD. It occurs when
impaired kidney function and irregular hormone levels cause alterations in bone mineral
metabolism, calcium and phosphate homeostasis. Changes start in the early stage of CKD and
will progress when GFR declines31.
Infections
Infections represent an important cause for the increased morbidity and mortality among
uremic patients, especially ESKD patients, mainly as a result of the altered functions of
neutrophils, monocytes, dendritic cells (DCs) and T cells, which are linked with higher risk
of infection32. Disabled immune response and infection susceptibility seen in peritoneal
dialysis patients also can to be triggered by impaired maturation of T helper lymphocytes33.
1.1.4 The role of immune cells in CKD
CKD leads to multifaceted changes in the immune system. On the one hand, CKD patients
have significantly increased blood levels of inflammatory cytokines, e.g. interleukin (IL)-10,
IL-6, tumor necrosis factor (TNF)-α, mainly due to decreased renal clearance, uremic toxins,
oxidative stress and elevated inflammatory cytokines originated from CKD complications34.
On the other hand, uremia and the imbalance of the internal environment suppresses immune
cells function. Under healthy conditions, immune cells such as neutrophils,
monocytes/macrophages, and lymphocytes maintain homeostasis and are effective to combat
any inflammatory or infectious immune response, for example clearing of pathogens or dying
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cells. In CKD patients, however, these immune defense mechanisms are impaired, leading to
a higher susceptibility to infections35. One immune mechanism is the inappropriately high
rate of dying cells (e.g. apoptotic cell death) under uremic conditions, which attenuates the
immune response36,37. This defective immune response in uremia is associated with an
imbalance between pro-inflammatory and anti-inflammatory mediators such as cytokines,
and pro-apoptotic and anti-apoptotic factors35.
Neutrophils in CKD
Neutrophils are polymorphonuclear leukocytes and have a short life span in human and
mouse circulation38. Neutrophils can be found in the bone marrow, blood, spleen, liver and
lung under physiological conditions39. In the absence of an inflammatory signal, neutrophils
die via apoptosis and are cleared by macrophages in the bone marrow and other tissues39.
During inflammation or infection, however, neutrophils are the first cells to enter the site of
inflammation, where they are able to remove debris and pathogens through various
mechanisms, such as releasing neutrophil extracellular traps (NETs), ​ ​ secreting proteases,
and producing reactive oxygen species (ROS). Neutrophils dysfunction will lead to an
increased risk of bacterial infection.
CKD leads to an impaired renal metabolic function resulting in the production of numerous
metabolic waste and toxic substances, which then accumulate throughout the body.
Neutrophils isolated from uremic patients show functional changes, such as reduced
chemotactic activity, lower cellular phagocytic response and reduced oxidative metabolism
leading to intracellular killing40. Neutrophils chemotactic function is critical for appropriate
recruitment to the sites of inflammation. Uremic toxins, such as urea, granulocyte inhibitory
protein41, modified ubiquitin42, leptin43, glucose-modified serum protein and free
immunoglobulin light chain37,44, resistin45, parathyroid hormone46, medium molecular weight
uremic toxin and endogenous polyamine, all are inhibitors that can suppress neutrophils
chemotactic activity.
Uremia also accelerates neutrophil apoptotic cell death, which may explain the low-grade of
chronic inflammation in patients with ESKD37. Interestingly, some uremic components have
also been found to delay neutrophils apoptosis, e.g. Ig light chains47, advanced glycation end
products44, oxidized low-density lipoproteins48, and TNF-α49. When apoptosis is delayed,
neutrophils survive longer and enhance their ability to fight against infections. However, such
neutrophils are more prone to necrosis, leading to a low-grade chronic inflammation by
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releasing pro-inflammatory cytokines32. In addition, initiation of apoptosis will reduce
necrosis-induced inflammation, hence attenuating the response to infection50. Further studies
are needed to explore the pro-inflammatory and anti-inflammatory properties of uremia.
Monocytes in CKD
Monocytes also play an essential role in the immune system. The three main functions of
monocytes are phagocytosis of invading pathogens and dying cells, presenting antigens to T
lymphocytes, and cytokine and chemokine production. Monocytes circulate in the
bloodstream for about one to three days before migrating into tissues, where they
differentiate into macrophages or dendritic cells (DCs)51. Monocytes also contribute to tissue
repair,52 further illustrating their relevance to health and disease. Similar to some other
primary and progenitor cells, monocytes are heterogeneous and plastic, with context-
dependent functions attributed to different subpopulations53.
The effects of uremia on monocytes are multifaceted, which is associated with dysfunction
and distribution of the different monocyte subsets54. Monocyte dysfunction has traditionally
been characterized by an overexpression of pro-inflammatory cytokines, such as IL-6 and
TNF-α, that were found increased in the serum of ESKD patients55. Importantly, an increase
in plasma levels of pro-inflammatory cytokines is associated with higher mortality in dialysis
patients56. When cultured with uremic serum, healthy monocytes and monocyte-derived DCs
exhibit decreased endocytosis and impaired maturation, similar to monocytes directly isolated
from ESKD patients.57 Besides that monocytes from hemodialysis patients were also reported
with decreased antigen presentation activity58, which might be related to the defective
immune response to infection. However, opposite to the pro-inflammatory function, Ando M,
et al. found that monocytes isolated from CKD patients on peritoneal dialysis release less IL-
1β and TNF-α in response to lipopolysaccharide (LPS) compared to healthy controls33, and
they explained this might be due to the reduced monocyte expression of toll-like receptor
(TLR)459.
1.2 Hyperuricemia
1.2.1 Hyperuricemia and associations with diseases
Uric acid (UA) is a metabolic breakdown product of purine nucleotides60. Birds and reptiles
mainly excrete UA in a crystalline form. In most mammals including rodents, UA can be
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degraded via the enzyme uricase into the more water soluble allantoin, a metabolite that is
freely excreted by the urine. Therefore, the serum UA levels are extremely low < 0.5-1 mg/dl.
However, humans and other higher primates lost uricase activity during evolution, as a
consequence, UA is the end product of the purine metabolism61. In addition, the continuous
UA production and the reabsorption during renal excretion, result in high serum UA levels in
humans, of above ~6.0 mg/dl for adult males62.
The excretion of UA depends mainly on three factors. First, the number of nephrons; Second,
the expression levels of various UA transporters in the renal tubules, such as urate transporter
1 (SLC22A12 / URAT1), glucose transporter 9 (SLC2A9 / GLUT9), ATP-binding cassette
transporter subfamily G member 2 (ABCG2), organic anion transport proteins (OAT) 1, 3, 4
and 10; and Third, the absence of other solutes that compete for secretion through these
transporters63 (discussed further in section UA transporter 1.2.2). An increase in UA
production and a decline in the excretion contribute to continuously elevated serum UA
levels in humans, better known as hyperuricemia (HU). Potential risk factors for HU are the
environment, dietary intake, impaired kidney function and genetic-related factors.
A reduced UA excretion occurs following GFR decline (decreased kidney filtration) due to
renal glomerular or tubular injury. Some diuretics, especially thiazide diuretics and other
drugs such as aspirin, pyrazinamide, levodopa, ethambutol, ethanol, etc. can also interfere
with the reabsorption of UA via renal tubules64. Organic acids, such as ketoacids and lactic
acid, can competitively inhibit renal tubular UA secretion65.
Furthermore, excessive UA production is common during the treatment of bone marrow and
lymphocyte-proliferative disorders. In leukemic patients that receive chemotherapy and
radiotherapy, a large number of cells dies and the nucleic acid metabolism accelerates,
leading to secondary HU66. Excessive production of endogenous UA may also result from a
purine-rich diet. Indeed, serum UA levels increase along with purine consumption in the
diet67.
Associations of hyperuricemia with diseases:
Kidney disease
Hyperuricemia is recognized as a risk factor for the development of AKI. This is clearly
shown during tumor lysis syndrome where enormous tumor cell death happens during
chemotherapy for haematological malignancies68. The tumor cell contents which are released
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into the blood stream can causes an increase in serum UA levels and severe renal
nephropathy69. Rasburicase has been approved for preventing and treating tumor lysis
syndrome because it can catalyzes UA into the more water-soluble allantoin70. However, it is
still not clear whether a decline of serum UA with rasburicase therapy will be beneficial for
decreasing kidney-related problems in the long-term71. Epidemiological and animal studies
have shown that in CKD persistent HU can lead to the deposition of UA crystals causing
renal inflammation and interstitial fibrosis, better known as chronic urate nephropathy72.
However, it is difficult to separate the independent effects of raising serum UA levels from
other pathologies associated with HU and kidney disease. As such, definitive causation has
not yet been proven in humans73.
Lesch-Nyhan syndrome
Lesch-Nyhan syndrome is a congenital anthraquinone metabolic deficiency disease of X-
linked recessive inheritance, characterized by the absence of hypoxanthine-guanine
phosphoribosyltransferase. A defect in this enzyme impairs hypoxanthine and guanine
degradation into inosine monophosphate and guanosine monophosphate but rather produce
UA, which induces formation of kidney stones early in life74.
Hypertension and cardiovascular disease
A number of epidemiological studies confirmed serum UA as an independent risk factor for
the onset of hypertension. When serum UA levels increase up to 59.5μmol/L, the relative risk
of hypertension onset increases to 25%75. Clinical studies found that 90% of patients with
essential hypertension have HU, compare to only 30% of patients with secondary
hypertension76. In addition, urate-lowering therapy (ULT) has been shown to reduce essential
hypertension77. However, it is still a matter of debate whether increased serum UA levels lead
to hypertension. For example, the association between hypertension and HU will decrease
due to aging patients and the duration of hypertension78,79.
The association of HU with heart disease is rather weak, and this link could potentially be
explained by the contribution of HU with hypertension. Studies have shown that HU can
induce endothelial dysfunction, an independent predictor of cardiovascular disease, by
decreasing eNOS activity in endothelial cells80 that can precede the development of
atherosclerosis81. Thus, HU is regarded as a risk factor for cardiovascular disease progression
and stroke (serum UA levels above 357 μmol/L and 416.5 μmol/L)82. This link is supported
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by a study demonstrating that as per 1 mg/dl increase in serum UA level, the risk of
cardiovascular death increases by 39%83.
Metabolic Syndrome, Type 2 diabetes and obesity
Metabolic syndrome is characterized by hyperinsulinemia, insulin resistance and low-grade
chronic inflammation. HU has been shown to be associated with the development of type 2
diabetes, but whether HU significantly contributes to the metabolic syndrome and diabetes
epidemic is still a debate84. Similar to cardiovascular disease, a recent study showed that the
contribution of HU with type 2 diabetes might be due to endothelial dysfunction and low-
grade chronic inflammation85. In contrast, another study showed a direct effect of sUA on
inhibiting pancreatic β-cells growth in vitro by inducing intracellular oxidative damage86.
Insulin resistance enlarged serum UA production during the glycolysis process and free fatty
acid metabolism, which directly leads to HU by increasing renal reabsorption of UA87.
Obesity can be classified as either metabolically healthy or unhealthy, with the later being a
risk factor for the development of cardiovascular disease88. Interestingly, HU was regarded as
one of the main predictors of unhealthy obesity. In addition, obesity can contribute to the
increased level of serum UA by promoting purine metabolism within adipose tissue89. It is
difficult to clarify whether HU contribute to the disease or the disease contributes to HU.
Gouty arthritis
One metabolic disorder which has been definitely related to HU, is gouty arthritis. Gout is
caused by the formation of MSU crystals in joints and periarticular spaces90, where they
induce a severe, self-limiting auto-inflammatory response91. As the crystallization event is
critical to the pathophysiology of gout, it is clear that HU is only a risk factor for gouty
arthritis, while the crystallization of UA and the ensuing auto-inflammation is the cause. This
is an important distinction, as it defines the immunological action of crystalline UA as
functionally different from sUA (discussed further in section 1.2.3). Although elevated serum
UA levels increase the risk of an acute gout attack92,93, only a minority of people with HU
(about 25%) develop gouty arthritis in their life time94,95.
Taken together, persistent HU is the core pathogenesis of gouty arthritis and chronic urate
nephropathy, as well as Lesch-Nyhan syndrome. In addition, epidemiological studies
document associations between persistent HU and cardiovascular disease, obesity or CKD
progression, but whether these associations involve causal relationships remains unclear.
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1.2.2 Uric acid transport
UA homeostasis depends on the balance of three factors: UA production, renal tubule
secretion and reabsorption, and intestine excretion. In gout patients, renal under-excretion is
the main cause for the development of HU96. It is estimated that the kidney accounts for
approximately 70% of urate excretion and the intestine for about 30%97. Proximal tubular
cells are the main cells involved in urate elimination from the plasma to the urine. Studies on
renal urate transport have been investigating this for many years60.
Urate transporters in the proximal renal tubule include the organic anion transporters
(SLC22A family: URAT1/SLC22A12, OAT4/SLC22A11 and OAT10/SLC22A13,
OAT1/SLC22A6 and OAT3/SLC22A8), multidrug-resistance proteins (MRP2/ABCC2,
MRP4/ABCC4, ABCG2), sodium-phosphate transporters (NPT1/SLC17A1 and
NPT4/SLC17A3), and the reabsorptive urate transporter Glut9/SCL2A9 (see Figure 2).
Among those, SLC2A9, URAT1, OAT1 and OAT3 seem to be the main transporters of renal
urate regulation, while the secretory transporter ABCG2 is more important for the intestinal
UA transport.
GLUT9/SLC2A9
GLUT9 is a member of the SLC2 family transporters and was initially identified as a class II
glucose/fructose transporter98. Recently, four genome-wide association studies (GWAS)
found that the SLC2A9 gene has a major effect on increased serum UA levels99–102. Two
isoforms of Glut9 were found strongly expressed in renal proximal tubular cells (RPTECs),
the long isoform Glut9a (-L) expressed on basolateral membranes and the short isoform
Glut9b (-S) expressed on apical membranes (Figure 2)103.
URAT1
URAT1 belongs to the SLC22A family and is expressed on the apical membranes of
RPTECs, where it is responsible for the urate-anion exchange of UA into the cell and the
export of small anionic counterions, such as lactate, out of the cell. Hypouricemic patients
have high urinary UA concentrations but lower UA levels in the serum indicating a mutation
in URAT1104.
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OAT1 and OAT3
Like URAT1, OAT1 and OAT3 also belong to the SLC22A family and are secretory anion-
exchange transporters. They are highly expressed in the basolateral surface of RPTECs and
well-known as major multi-specific drug transporters. They can transport a variety of organic
anion drugs, classic physiological probes, as well as many metabolites and signaling
molecules105.
ABCG2
The urate secretory transporter ABCG2, an ATP-binding cassette sub-family G member2, is
expressed in the apical membranes of RPTECs and intestinal epithelia. Unlike most other
urate transporters, which largely mediate renal tubular handling of UA, the expression of
ABCG2 in the intestine is much higher than in the kidney, implying that this gene mainly
account for intestinal secretion of UA106. Lower gut excretion and higher serum UA level
were found in ABCG2 knockout mice107.
Currently, there are three mechanisms through which UA levels can be pharmacologically
manipulated: 1), Xanthine oxidoreductase (XOR) inhibitors such as allopurinol and
febuxostat; 2), Recombinant uricases such as rasburicase and pegloticase, and 3), Uricosuric
drugs to increase renal UA excretion such as lesinurad and probenecid to target URAT1,
OAT1, OAT3 and OAT4108,109, and benzbromarone for URAT1110. There are also secondary
uricosurics that are primarily used in patients with other comorbidities, such as losartan for
hypertension and fenofibrate for hyperlipidemia, both inhibiting URAT1.
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Figure 2: Urate transporters in the proximal tubule of the kidney. Transporters involved in
reabsorption of urate from tubule lumen into blood are shown in violet, and those involved in
secretion of urate from blood into tubule lumen are shown in blue. Abbreviations: Glut, glucose
transporter; OAT, organic anion transporter; URAT, urate transporter; NPT, sodium phosphate
transporter; MRP, multidrug resistant protein.
1.2.3 Immunological effects of uric acid
Crystalline monosodium urate (MSU)
MSU crystals are the causative agent for gouty arthritis, because they activate the NLRP3
inflammasome leading to IL-1β maturation from its precursor and release111. This in turn is a
characteristic feature of an acute inflammatory response to MSU crystals within the joints
(discussed further in section 1.3). In addition, MSU crystal deposits in the kidney can also
induce chronic inflammation, interstitial fibrosis and glomerulosclerosis112.
In a study by Shi, et al.113, the authors show that UA acts as a strong endogenous immune
adjuvant that is released from dying cells. They found that UA not only can improve adaptive
immune responses but also could potentiate the generation of CD8 T-cell responses in vivo,
indicating that MSU crystals are responsible for this adjuvant effects. Accordingly, effect of
MSU crystals as an adjuvant has been studied in a murine cancer model wherein MSU
crystals and M. smegmatis co-injection promoted tumor progression through the rapid
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induction of monocyte-derived DCs114. Most studies have focused on the crystalline form of
UA; however, the functional role of sUA remains less clear.
Soluble UA
Soluble UA has powerful antioxidant properties similar to ascorbic acid 62,115. For example,
sUA acts as a scavenger for peroxyl and hydroxyl radicals, singlet oxygen and oxygen
radicals62. It can chelate metal ions to prevent catalyse free-radical reactions, e.g. iron ion-
mediated ascorbic acid oxidation or Cu2+- mediated LDL oxidation115,116. These antioxidant
effects together may constitute protective effects of UA in aging and cancer62. Human studies
further emphasize neuroprotective effects of high serum UA levels as an antioxidant, for
example HU protects against the progression of Parkinson’s disease and other kind of
neurodegenerative diseases117–119. Furthermore, in human macrophages, sUA reduces LPS-
induced TNF-α production and increases IL-10 production. The authors speculated that the
pathological concentration of UA in mice do not induce an immune response in human
immune cells, thus sUA exhibits anti-inflammatory activity rather than pro-inflammatory
properties in human macrophages120.
On the other hand, sUA has been identified as a danger signal that can alert the immune
system to dying cells121. In vitro studies have shown that sUA inhibits IL-1Ra function in
human peripheral blood mononuclear cells, leading to TLRs activation and pro-inflammatory
cytokine production122, and activates the AKT-PRAS40 autophagy pathway in human
monocytes123. In a mouse model of unilateral ureteral obstruction (UUO), sUA activates the
NLRP3 inflammasome in bone marrow-derived macrophages and aggravates kidney
fibrosis120. Besides immune cells, sUA also has the ability to activate adipocytes with
enlarged ROS production and oxidative stress124, and decreased anti-inflammatory adipokine
adiponectin production125. Another study showed that sUA also activates NFκB and MAPK
signaling, and cell proliferation in vascular smooth muscle cells80,126,127. These results would
suggest that sUA directly contributes to oxidative stress and inflammation.
Taken together, elevated levels of sUA seem to be a “double-edged sword” depending on the
clinical context. The effects of sUA can be on one hand protective and on the other hand pro-
inflammatory. Further studies are needed to unravel the exact molecular mechanisms because
an association does not necessarily imply causality. Therefore, well-designed clinical studies
and animal models are needed.
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1.3 Acute gouty arthritis
Gout is one of the most common arthritis diseases and characterized by MSU crystals
deposition in episodic joints and soft tissues. Acute gouty arthritis is triggered when MSU
crystals interact with resident synoviocytes, like macrophages, which elicit an acute
inflammatory response, but it is self-limited and will be resolved within a few days or 1 to 2
weeks128. The prevalence of gout increased globally over the last half century. For example,
from 1970 to 1990 in England, gout rates rose from 0.3% to 1.0%129 and from 1990 to 1999
in the US, from 2.1% to 4.1% on men above 75 years old130. In eastern China, the incidence
is 1.14% in 2008 compared to the rare case in 1980131.
1.3.1 Gout Risk factors and Management
Gout is a complex disorder, which is induced by multiple risk factors. The central element of
gout is MSU crystal. Thus, risk factors contributing to HU and MSU crystal nucleation and
growth are also risk factors for gout. Both non-genetic and genetic factors associate with
progression of gout.
Non-genetic risk factors
Well-described dietary risks for HU and incidence of gout are: the high purines food
(especially meat and seafood), soft drinks, fructose, and ethanol (beer and spirits)132. Both
acute purine-rich foods intake and alcohol consumption increase recurrent gout attacks133,134.
Sugars were also reported as a risk factor of both HU and gout by influencing serum UA
level via the urate transporter GLUT9135. In contrast, coffee, dairy products and vitamin C
were reported as UA lowering diet136,137. Why these foods affect the incidence of gout is still
not fully understood. Currently, there are two possible explanations one being the increased
generation of UA via hepatic metabolism138 and the other modulating the function of UA
transporters104.
Aging causes a decline in kidney function associated with decreased excretion of UA, which
can lead to HU and gout. One reason might be the alterations of connective tissues as people
get older, which can serve as a nucleation spot for MSU crystals94. Men tend to have higher
UA levels than women, especially compared to pre-menopausal women, following with 3 to
4 times higher gout risk in men139. Ljubojevic M, et al. showed that the estrogen has a
uricosuric-like effect, which may explain the lower serum UA levels and less gout rate in
young females140.
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Comorbid conditions, for example CKD, obesity, HU, anaemia, and hypertension are risk
factors for HU (discussed in section 1.2.1) and were reported to increase the development of
gout. Medications, e.g. diuretics, cyclosporine, tacrolimus, angiotensin-converting-enzyme
inhibitors, non-losartan angiotensin II receptor blockers, β-blockers, pyrazinamide, ritonavir
are also associated with the risk of gout128. In addition, factors facilitating MSU crystal
formation, such as temperature, pH, salt concentration and cartilage matrix components are
believed to be accountable for a higher incidence of gout attacks141.
Genetic risk factors
Compared with environmental factors, genetic-related risk factors are more recognized
recently by GWAS surveys. For example, genetic variations were identified focusing on the
loci that are related to controlling urate levels (see in section 1.2.2). However, the loci that
control MSU crystals formation and inflammatory response pathways are still poorly
understood142.
Gout Management
Gout management includes short-term treatment of acute inflammatory flares as well as long-
term management. For acute gout attacks, a rapid and effective treatment of MSU crystal-
induced inflammation is necessary to decrease joint pain and swelling in patients. There are
three common anti-inflammatory drugs recommend: First, non-steroidal anti-inflammatory
drugs (NSAIDs) including naproxen, ibuprofen, indomethacin and ketorolac, and non-
selective inhibitors of cyclooxygenase; Second, colchicine, which will bind to neutrophils
and hence inhibits the inflammatory response of neutrophils; and Third, glucocorticoids that
are usually used for patients where the first two line treatment options do not provide enough
pain release143. These drugs mentioned above can be used alone or in combination depending
on the patient condition. In addition, anakinra144, an IL-1 receptor blocker, is another
potential drug being used to decrease IL-1β levels, because IL-1β is a critical pro-
inflammatory cytokine released after MSU crystal-induced NLRP3 inflammasome
activation111, as well as the IL-1 blocking-related agents rilonacept and canakinumab145.
For long-term gout management the central strategy is to lower serum UA levels to prevent
recurrent gout attacks and to protect joint damage. Recently, the American college of
Rheumatology guidelines suggest that UA levels should be below 6.0 mg/dl and if the signs
continue, it should be lower than 5 mg/dl146. There are different strategies for ULT. The first
recommended therapy from the American college of Rheumatology guidelines are xanthine
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oxidase inhibitors, which include allopurinol (a purine analog) and febuxostat (a non-purine
secective, non-competitive inhibitor), both prevent UA production. Secondly, uricosurics
such as probenecid and benzbromarone, which are organic acids preventing UA reabsorption
and increase kidney UA excretion. Thirdly, the uricoslytic drug pegloticase, a recombinant
uricase, can convert UA into the more water-soluble allantoin. Other guidelines also suggest
a reduction in fructose and alcohol consumption, avoiding high purine food, weight loss,
increasing exercise, and eliminating unnecessary medications that are considered to benefit
gout management147.
1.3.2 Mechanisms of acute gouty arthritis
The synovial joint where the gout flare usually occurs consists of the synovial membrane and
a variety of cellular components including fibroblasts, adipocytes, collagen fibers,
proteoglycans and two main cell types: type A and type B synovial lining cells148. The type A
cells are derived from monocytes known as tissue macrophage-like synoviocytes149. These
macrophage-like cells can remove cellular and particulate debris like MSU crystals via
phagocytosis. And the type B cells are connective tissue fibroblast-like cells, which origin
from the mesenchyme150. The synovial membrane is also enriched with capillaries and
postcapillary venules that together maintain joint homeostasis.
Monosodium urate crystallization
MSU crystals formation and precipitation in the synovial cavity is the dominant step for the
induction of an acute gout attack (Figure 3)151. However, the mechanisms behind the
crystallization process in vivo are still not fully understood. A decrease in UA solubility and
MSU nucleation are critical steps for the priming of a gout attack152. Although the UA
concentrations in gout patients are similar in plasma and synovial fluid, the plasma represents
a better solvent for MSU153. Compared with the plasma environment, peripheral joints have a
lower tissue temperature, ionic strength and pH, which may account for the lower solubility
of UA154. Synovial fluid components, such as gamma globulin and type I collagen fibers,
were also found to increase MSU nucleation, which was demonstrated in an in vitro study
with synovial fluid from gout patients152.
Acute immune response to MSU crystals
Not only is the solubility of UA influenced by its binding to plasma proteins, including
inflammatory proteins, connective tissue and matrix proteins, apolipoproteins, histones, and
adaptive immunity associated proteins like immunoglobulins IgG and complement155, but
Introduction 17
also its inflammatory potential. These protein-coated MSU crystals act as an inflammatory
danger signal upon phagocytosis by resident macrophages, hence triggering cell membrane
signals, for example the activation of the NOD-like receptor protein 3 (NLRP3)
inflammasome. NLRP3 inflammasome activation leads to IL-1β maturation and release, as
well as other multiple secondary inflammatory cytokines, chemokines and
prostaglandins111,155.
Amplified inflammation
Cytokines, especially IL-1β, released from macrophages and other cells156, act as chemotactic
factor, and subsequently leads to a rapid recruitment of neutrophils to the site of MSU
crystals deposition amplifying the inflammatory response91. This neutrophil-centered process
also includes mast cell degranulation157, complement activation158 and the expression of
endothelium-derived selectins159. Once migrated in the joint, neutrophils interact with MSU
crystals, inducing inflammatory mediators like nitric oxide, ROS, leukotriene B4,
prostaglandins and other mediators that can damage tissue and cause pain91. MSU crystal-
induced neutrophil activation also promotes monocyte/macrophages recruitment and
activation (Figure 3).
Resolution of gouty arthritis
One characteristic feature of acute gouty arthritis, which differs from other acute
inflammatory responses, is that a gout flare usually resolves within a few days or several
weeks even in the absence of treatment160. Some negative mediators were found in synovial
fluid during acute flares that might be involved in resolving inflammation, such as
transforming growth factor-β, IL-10, IL-1R antagonist, TNFR-I/II, suppressors of cytokine
signaling 3 and cytokine inducible SH2-containing protein161. In addition, inflammatory
mediators and cells deactivation, apoptotic neutrophils clearance by recruited monocytes or
resident macrophages, and enhanced expression of anti-inflammatory receptors also
contribute to suppressing MSU crystal-induced inflammation91. The changed physical
properties of MSU crystals may also comprise the resolution stage152. A recent in vivo study
showed that aggregated NETs due to a high density of neutrophils can have a positive role in
favoring the resolution of MSU crystal-induced inflammation by degrading cytokines and
chemokines (Figure 3)162.
Current therapies for managing gout are designed to suppress the different phases and stages
of MSU crystal-induced inflammation146. Although the mechanisms of gout are well known
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and effective management is available, many uncertainties still remain. For example, why
does the acute attack self-resolve and why are MSU crystal deposits (also known as tophi)
present within the synovium without inducing an inflammatory response? Why do MSU
crystals form preferentially at certain sites? Why do tophi form in some individuals and not in
others? All these observations would suggest that the existing mechanisms can modify the
acute gout attack. So a better understanding of both the pro- and anti-inflammatory pathway
may help to develop new strategies for the management of gout.
Figure 3: Mechanisms of acute gout attack. A decrease in UA solubility and MSU nucleation are
critical steps for the priming of a gout attack. Deposited MSU crystals act as an inflammatory danger
signal upon phagocytosis by resident macrophages, hence triggering cell membrane signals, for
example the activation of the NOD-like receptor protein 3 (NLRP3) inflammasome. NLRP3
inflammasome activation leads to IL-1β maturation and release, as well as other multiple secondary
inflammatory cytokines, chemokines and prostaglandins. These signals subsequently initiate a rapid
recruitment of neutrophils to the site of MSU crystals deposition, where they generate superoxide and
IL-8, and release NETs, amplifying the inflammatory response. MSU crystal-induced neutrophils
activation also promotes monocyte/macrophages recruitment and activation. Recruited monocytes or
resident macrophages take up apoptotic neutrophils and produce anti-inflammatory factors, such as
TGF-β, contributing to the resolution. Recently, aggregated NETs were reported to have a positive
role in favoring the resolution of MSU crystal-induced inflammation by degrading cytokines and
chemokines. MSU, monosodium urate crystals; NETs, neutrophil extracellular traps; TGF,
transforming growth factor; TNF, tumor necrosis factor; IL, interleukin.
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1.3.3 The role of immune cells in acute gouty arthritis
During an acute gout attack, both innate immune cells (monocyte/macrophages, neutrophils,
mast cells and NK cells163) and adaptive immune cells (T cells and B cells164) are involved.
Among them, monocytes/macrophages and neutrophils play a key role during the
inflammatory response to MSU crystals. This section will focus on what is currently known
about the cellular response.
Monocytes and macrophages
The initiation of an acute gout attack is characterized by NLRP3 inflammasome activation
and IL-1β release by resident macrophages111. Unlike monocytes, macrophages require two
signals for MSU crystal-induced NLRP3 inflammasome activation: priming and activation
signal. Subsequently, caspase-1 is recruited and activated, and promotes maturation of pro-
IL-1β into active IL-1β91. The IL-1β-mediated inflammatory response is a key feature of
acute gout arthritis165.
Like neutrophils, monocytes also require adhesion molecules and chemokines, such as
monocyte chemoattractant protein-1 (MCP-1) and IL-8166 for their migration to the site of
MSU crystal-induced inflammation. Furthermore, cyclooxygenase-2167 and leukotriene B4168
were reported to act as chemoattractants for monocyte recruitment. In a model of MSU
crystal-induced peritonitis, monocytes infiltrated into the peritoneum after 4-8 hours169.
Following their activation by MSU crystals, monocytes released pro-inflammatory mediators,
such as IL-1β, TNF-α, IL-6 and CCL-2, and finally differentiated into a pro-inflammatory
M1-like macrophage phenotype over time157,169,170.
Apart from their role in the initiation phase, growing evidence shows that monocyte-derived
macrophages also play a critical role during the resolution phase of acute gout. Human
CD14+ monocyte-differentiated macrophages stimulated with MSU crystals in vitro have
been shown to produce the anti-inflammatory cytokine transforming growth factor (TGF)-β
but decreased levels of pro-inflammatory cytokines171. This indicated that macrophages
switched from a pro-inflammatory into an anti-inflammatory phenotype. In addition, the
phagocytosis of apoptotic neutrophils by macrophages triggers the production of TGF-β as
well as the safe removal of MSU crystals172. The cellular characterization of gout tophi
revealed that the tophus is composed of central MSU crystalline material with mast cells, B
and T cells, and plasma cells surrounded by macrophages and multinucleated macrophage-
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like cells173, highlighting the importance of monocytes and macrophages during the
resolution of gout.
Neutrophils
Neutrophils are well known for amplifying acute gouty inflammation and several
mechanisms have already been reported. Inflammatory signals initiated by MSU crystals,
activate the endothelium of blood vessels and induce a series of molecular processes on
endothelial cells, for example, the expression of the neutrophil adhesion molecules ICAM-1,
VCAM-1 and E-selectin174. This upregulation of neutrophil adhesion molecules on
endothelial cells allows neutrophils to slowly roll and firmly adhere to the endothelium
before migrating to the site of inflammation. Meanwhile, vascular dilatation and increased
permeability also support neutrophil transmigration175 along chemokine gradients, such as IL-
8, nitric oxide, leukotriene B4 and IL-1176.
Neutrophils represent a positive feedback loop whereby some extravasated neutrophils
phagocytose MSU crystals leading to degranulation or direct crystal lysis of lysosomal177,
cell membrane ruptures, IL-8 release and further neutrophil recruitment. This in turn triggers
the release of further inflammatory mediators, such as prostaglandin E2, nitric oxide,
leukotriene B4, ROS, S100A8, S100A9, IL-1, and IL-8, as well as other mediators for tissue
damage178. In vitro and in vivo studies showed that low concentrations of MSU crystals and
culture supernatants from MSU crystal-stimulated neutrophils decreased the number of
apoptotic neutrophil death179, whereas at high concentrations MSU crystals cause NET
formation, known as NETosis, associated with ROS production, autophagy and PI3K
signaling162,180–182.
Neutrophils were thought to contribute to the pathophysiology of sterile inflammation due to
their cytotoxic potential. However, studies now showed that neutrophils also play an active
role in resolving acute inflammation. As professional phagocytes, neutrophils are capable of
phagocytosing apoptotic neutrophils, which triggers the production of TGF-β and suppresses
superoxide production and IL-1β release by MSU crystal-activated neutrophils in vitro183. In
response to MSU crystals, neutrophils form NET-like structures associated with the release of
proteases that can trap and cleave pro-inflammatory cytokines162. These trapped pro-
inflammatory cytokines and chemokines, such as TNF-α, IL-6 and MCP-1, are then degraded
and inactivated184. Furthermore, Gagné and colleagues found that neutrophils once activated
by MSU crystals down-regulate the myeloid inhibitory C-type lectin, which leads to
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decreased IL-8 production185. As a result, decreased IL-8 production impaired neutrophils
recruitment and thereby suppresses inflammation. This might be one possible mechanism for
the self-limiting nature of gout.
1.4 The prevalence of gouty arthritis in CKD
Hyperuricemia and gout
Many epidemiological studies show that HU is strongly associated with gout and that the
prevalence is increasing worldwide. In the UK and Germany, compared with those serum UA
below 6mg/dl, the odds ratio in patients with serum UA between 6 to 7 mg/dl is 1.33 and 1.37,
and in those with UA levels above 9 mg/dl 2.15 and 2.18, respectively93. In Israel, between
2000 to 2012, a follow up study found that asymptomatic HU (men above 7.0 mg/dl and
women above 5.6 mg/dl) is significantly associated with the risk of developing gout,
especially for men who have severe HU186. Recently, Dalbeth N, et al. included 18889 gout-
free patients from four publicly available cohorts and calculated the incidence of gout based
on the reference serum UA level, and they found that serum UA level is a strong non-linear
concentration-dependent predictor for the incidence of gout187. Interestingly, only about half
of those with serum UA concentrations ≥10mg/dl developed clinically evident gout over 15
years, indicating a role for prolonged HU and additional factors in the pathogenesis of gout187.
There is no doubt that HU is a requisite for the precipitation of MSU crystals. However, it
seems like that HU is not always the precursor of acute gout attack. A rapid correction of HU
with allopurinol can trigger acute gout attacks in patients188 and some patients even with
normal serum UA levels (lower than 6.8mg/dl) can develop acute gout189. Furthermore, some
individuals with persistent HU never experience gout attacks in their lives, especially those
patients who suffer from CKD and HU160. This would indicate that HU alone is not essential
for gout but rather implies a more complex role for HU in gout.
Hyperuricemia and gout in CKD
Hyperuricemia is common in CKD patients due to a decline in the excretory function of the
kidneys190. Reduced GFR and the presence of albuminuria in CKD patients are associated
with HU191. The cross-sectional study NHANES 2007-2010 in the US including 10,814 CKD
patients with HU demonstrated that the prevalence of self-reported gout was 5.7% in CKD
patients with an eGFR of 60-89 ml/min/1.73 m2, 12.9% with an eGFR of 30-59 ml/min/1.73
m2 and 29.8% in CKD patients with an eGFR <30 ml/min/1.73m2192.The German chronic
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kidney disease (GCKD) study including 5,085 CKD patients also showed an increased
prevalence of self-reported gout is common among patients with CKD and that lower eGFR
(<30 ml/min/1.73 m2) is strongly associated with gout (35.6%) and in CKD patients with an
eGFR ≥60 ml/min/1.73 m2 (16.0%)193. In patients with ESKD receiving maintenance dialysis
the frequency of gouty arthritis decreases compared to CKD patients despite persistent HU
possibly due to metabolic perturbations of uremia194,195. However, while only a minority of
non-CKD individuals has HU186,196, nearly all individuals with CKD/ESKD display persistent
HU. This raises the question why do not all CKD/ESKD patients suffer from gouty arthritis?
Currently, the molecular mechanisms are not well understood to why the prevalence of gouty
arthritis is much lower than expected although all CKD/ESKD patients have persistent HU. It
is intriguing to suggest that HU may rather act as a suppressor of the inflammatory response
to MSU crystals in acute gouty arthritis.
Challenges of urate-lowering therapy in CKD
According to the 2012 ACR guidelines, ULT is recommended for patients with frequent
acute gout flares (>1 per year)146. Pharmacological management of gout in patients with CKD
is suboptimal. Whether HU contributes to the progression of CKD or is just an accidental
event due to loss of renal function has been argued for many years73,191,197,198. Currently, there
is no strong evidence recommending ULT in asymptomatic HU patients to delay the
progression of CKD. Therefore, larger human trails on ULT in CKD and ESKD patients with
a long follow up period are needed for a better understanding199.
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2 Hypothesis
Crystalline UA induces inflammation, and HU predisposes to MSU formation. Indeed,
persistent HU is associated with gouty arthritis and it is also an important characteristic
feature of CKD/ESKD. Nevertheless still only a minority of patients with persistent HU such
as advanced CKD-related HU experiences gouty arthritis. Therefore, we hypothesized that
HU not only is a substrate for MSU formation but also might exert independent
immunomodulatory effects during sterile inflammation induced by MSU crystals.
Accordingly, the specific aims of this thesis were:
1. To investigate, whether HU has immunomodulatory effects on the acute inflammatory
response in vivo during experimental gouty arthritis in CKD, e.g. the release of
inflammatory mediators, the leukocyte rolling, adhesion and extravasation induced by
MSU crystals.
2. To investigate the effect of sUA on human blood neutrophils from healthy volunteers
and CKD/ESKD patients ex vivo, e.g. the functional impact of sUA on human
neutrophil activation and migration, as well as NET formation (DNA, MPO and NE
release) in response to MSU crystals.
3. To evaluate the immune-modulatory role of sUA on the inflammatory function of
human blood CD14+ monocytes from healthy volunteers and CKD/ESKD patients ex
vivo and on human monocytic THP-1 cells in vitro, e.g. the uptake of sUA and the
associated phenotype changes regarding the release of inflammatory mediators.
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3 Materials and methods
3.1 Instruments and Reagents
3.1.1 Instruments
Analytic Balance, BP 110 S Sartorius, Göttingen, Germany
Mettler PJ 3000 Mettler-Toledo, Greifensee, Switzerland
Type B5060 EC-CO2 Heraeus Sepatech, München, Germany
Leica DC 300F Leica Microsystems, Cambridge, UK
Olympus BX51 Olympus Microscopy, Hamburg, Germany
Tecan, GENios Plus Tecan, Crailsheim, Germany
Heraeus, Minifuge T VWR International, Darmstadt, Germany
Heraeus, Biofuge primo Kendro Laboratory GmbH, Hanau, Germany
ABI prism ™ 7700 sequence detector PE Biosystems, Weiterstadt, Germany
qRT-PCR syber green LC-480 Roche, Mannheim, Germany
Beckman DU® 530 Beckman Coulter, Fullerton, CA, USA
Nanodrop PEQLAB, Erlangen, Germany
Cryostat RM2155 Leica Microsystems, Bensheim, Germany
FACSCalibur BD Biosciences, CA, USA
Homogenizer ULTRA-TURRAX T25 IKA GmbH, Staufen, Germany
Microtome HM 340E Microm, Heidelberg, Germany
pH meter WTW WTWGmbH, Weilheim, Germany
Thermomixer 5436 Eppendorf, Hamburg, Germany
Vortex Genie 2™ Bender & Hobein AG, Zürich, Switzerland
Water bath HI 1210 Leica Microsystems, Bensheim, Germany
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3.1.2 Reagents
Antibodies Source
Anti-human PSGL-1 BioLegend, Fell, Germany
Anti-human VLA-4a BioLegend, Fell, Germany
FITC linked Anti-mouse Ly6G BioLegend, Fell, Germany
PE linked Anti-mouse Ly6C BioLegend, Fell, Germany
PE/Cy5 linked Anti-mouse CD45 BioLegend, Fell, Germany
APC linked Anti-mouse CD11b BioLegend, Fell, Germany
FITC linked Anti-human CD11b BioLegend, Fell, Germany
PE linked Anti-human CD66b eBiosciences, Germany
APC linked Anti-human CD15 eBiosciences, Germany
FITC linked Anti-human CD14 BioLegend, Fell, Germany
PE linked Anti-human CD15 BioLegend, Fell, Germany
APC linked Anti-human CD16 BioLegend, Fell, Germany
Cit. histone H3, red Cell Signaling, Danvers,MA
FcR block BD Biosciences, Germany
Neutrophil elastase, green Santa Cruz biotechnology, San Cruz, CA
Anti-DNA Roche, Germany
Anti-human MPO AbD Serotec, Raleigh, North Carolina
mAB24 (clone 24) Gallios, Beckman Coulter
LFA (clone HI111) BioLegend, Fell, Germany
MAC-1 (clone ICRF44) BioLegend, Fell, Germany
Anti-human TNF-α BioLegend, Fell, Germany
Anti-human IL-6 BioLegend, Fell, Germany
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Kits Source
mouse IL-6 Ray Biotech, norcross, USA
mouse IL-1β Ray Biotech, norcross, USA
mouse CXCL-1 EBiosciences, Germany
mouse TNF-α Biolegend, San Diego, CA
PicoGreen dsDNA kit Fisher Scientific, Schwerte, Germany
Creatinine FS DiaSys Diagnostic System, Holzheim, Germany
Urea FS DiaSys Diagnostic System, Holzheim, Germany
Uric acid BioAssay Systems, Hayward, USA
RNA extraction Kit Qiagen GmbH, Düsseldorf, Germany
Drugs and Treatment Source
MSU Invivogen, SanDiego, USA
Uric acid Sigma-Aldrich, Taufkirchen, Germany
Rasburicase EBiosciences, Germany
PMA Sigma-Aldrich, Taufkirchen, Germany
fMLP Immunotools, Friesoythe, Germany
Human CXCL8 Immunotools, Friesoythe, Germany
Human IL-1β Immunotools, Friesoythe, Germany
LPS Sigma-Aldrich, Taufkirchen, Germany
GolgiPlug BD Biosciences, Germany
Human TNF-α Sigma-Aldrich, Taufkirchen, Germany
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Cell culture Source
RPMI-1640 medium GIBCO/Invitrogen, Paisley, Scotland, UK
FCS Biochrom KG, Berlin, Germany
Dulbecco’s PBS (1×) PAN Laboratories GmbH, Cölbe, Germany
Trypsine/EDTA (1×) PAN Laboratories GmbH, Cölbe, Germany
HBSS GIBCO/Invitrogen, Paisley, Scotland, UK
Fetal bovine serum Biochrom, Berlin, Germany
Glutamine Gibco, Invitrogen, Grand Island, NY, USA
Penicillin/Streptomycin (100×) PAN Laboratories GmbH, Cölbe, Germany
3-um Transwell filter Sigma-Aldrich, Taufkirchen, Germany
HEPES buffer Sigma-Aldrich, Taufkirchen, Germany
Chemicals Source
AEC Substrate Packing Biogenex, San Ramon, USA
Beta mercaptoethanol Roth, Karlsruhe, Germany
Bovines Serum Albumin Roche,Diagnostics,Mannheim, Germany
Calcium chloride Merck, Darmstadt, Germany
Calcium dihydrogenphosphate Merck, Darmstadt, Germany
Dextran Sigma-Aldrich, Taufkirchen, Germany
DMSO Merck, Darmstadt, Germany
EDTA Calbiochem, SanDiego, USA
Ethanol Merck, Darmstadt, Germany
HCl (5N) Merck, Darmstadt, Germany
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Monopotassium phosphate Merck, Darmstadt, Germany
Penicillin Sigma, Deisenhofen, Germany
Potassium chloride Merck, Darmstadt, Germany
Sodium azide Roche, Germany
Sodium dihydrogenphosphate Merck, Darmstadt, Germany
Streptomycin Sigma, Deisenhofen, Germany
Trypan Blue Sigma, Deisenhofen, Germany
Xylol Merck, Darmstadt, Germany
4% Formalin Merck, Darmstadt, Germany
Miscellaneous Source
RT-PCR primers Metabion, Munich, Germany
HumanCD14 microbeads Miltenyi Biotec, Bergisch Gladbach, Germany
AccuCheck counting beads Thermo Fisher Scientific, München, Germany
RNAlaterTM Soln Invivogen, SanDiego, USA
Distilled water (DNAse/RNase free) GIBCO/Invitrogen, Paisley, Scotland, UK
Sunflower seed oil Sigma, Deisenhofen, Germany
Inosine Sigma, Deisenhofen, Germany
Tamoxifen Sigma, Deisenhofen, Germany
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3.2 Mouse models procedures
3.2.1 Maintenance and ethical approvals
All animal experiments were performed in accordance with the directive 2010/63/EU of the
European parliament and upon approval by the local government authorities Regierung von
Oberbayern (reference number: ROB-55.2-2532.Vet_02-15-189). The experimental mice
were housed in groups of maximum five in filter-top cages with bedding and pulp, 22.2 °C
and a 12 hours light/dark cycle. Mice had free access to food and water ad libitum. Cages,
litter, nest lets, houses, food and water were sterilized by autoclaving at 120 °C and 1 bar
pressure for 20 minutes.
3.2.2 Mouse model of hyperuricemia and chronic kidney disease
Six-weeks old Alb-creERT2;Glut9lox/lox mice and Glut9lox/lox control mice (kindly provided by
Frédéric Preitner and Bernhard Thorens, University of Lausanne, Center for Integrative
Genomics, Lausanne, Switzerland) were injected with tamoxifen every alternate day for one
week200. Then the Alb-creERT2;Glut9lox/lox mice were randomized into two groups: one
group (n=7) received a high-fat diet enriched with inosine (Research Diets Inc., New
Brunswick, USA) to induce hyperuricemia with chronic kidney disease (HU+CKD) and the
second group (n=7) received a chow diet with inosine (Ssniff, Soest, Germany) to induce
only hyperuricemia (HU) without any renal impairment for 22 days. The Glut9lox/lox mice
(n=7) received only chow diet with inosine for 22 days and served as control group (healthy),
as shown in Figure 4.
Figure 4: Flow chart of mouse model of HU with and without CKD.
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3.2.3 Air pouch model of acute gouty arthritis
Alb-creERT2;Glut9lox/lox (n=18) and Glut9lox/lox (n=10) mice were injected with tamoxifen.
Then the Alb-creERT2;Glut9lox/lox mice were randomized into two groups: the HU+CKD
group (n=10) was fed a high-fat diet with inosine and the HU group (n=8) a chow diet with
inosine. The Glut9lox/lox control mice (n=10) were fed a chow diet enriched with inosine. All
the groups of mice were injected with MSU crystals (5 mg per mouse, Invivogen, San Diego,
USA) into a pre-existing air pouch on day 21, a well-established mouse model of acute gouty
arthritis162. After 12 hours, all three groups of mice (healthy, HU and HU+CKD) were
sacrificed and blood, kidneys, and air pouch fluid collected for further analysis, as shown in
Figure 5. To lower the UA levels in the blood, Alb-creERT2;Glut9lox/lox mice (n=20) were
injected with tamoxifen and placed on a high-diet with inosine for 22 days. Then the mice
were randomized into four groups: the rasburicase treated two groups were administered
intravenously with rasburicase on day 16, 18 and 20 (10 mg/kg body weight) prior to MSU
crystal (n=6) or vehicle (n=6) injection into the air pouch, the non-treated two groups with
MSU crystals (n=4) or vehicle (n=4) injection has the same procedure as shown in Figure 6.
Figure: 5: Flow chart of air pouch model of acute gout in hyperuricemic mice with and without CKD.
Figure 6: Flow chart of rasburicase treatment in the air pouch model in hyperuricemic mice with and
without CKD.
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3.2.4 Intravital microscopy of the cremaster muscle
Intravital microscopy was conducted on an OlympusBX51 WI upright microscope, equipped
with a 40x water immersion objective (Olympus, 0.8NA) and a CCD camera (KAPPA CF 8
HS) as previously reported201. To induce inflammation, male Alb-creERT2;Glut9lox/lox (n=8)
and Glut9lox/lox (n=3) mice were injected with tamoxifen. The Alb-creERT2;Glut9lox/lox mice
were randomized into two groups: the HU+CKD group (n=4) was fed a high-fat diet with
inosine and the HU group (n=4) a chow diet with inosine. The Glut9lox/lox control mice (n=3)
were fed a chow diet enriched with inosine. After 22 days, all the groups of mice were
received an intrascrotal injection of 0.5 mg MSU crystals per mouse 4 hours prior to
exteriorization of the cremaster muscle, as shown in Figure 7. During the observation, the
muscle was constantly superfused with thermo-controlled and gased superfusion bicarbonate
buffer202,203 and up to 6 postcapillary venules were recorded for later analysis. Centerline
velocities of every recorded vessel were measured with a dual photodiode and converted to
mean blood flow velocities (Circusoft Intrumentation). Rolling flux fraction, leukocyte
adhesion and leukocyte rolling velocities were analyzed offline on the basis of the recorded
movie sequences using FIJI software (Schindelin 2012) (n = 13 vessels of healthy mice, n =
23 vessels of HU mice, n = 22 vessels of HU+CKD mice). To assess leukocyte extravasation,
exteriorized cremaster muscles were removed after intravital microscopy, fixed in 4% of
paraformaldehyde, stained with Giemsa (Merck, Darmstadt, Germany) and mounted using
Eukitt mounting medium (Sigma-Aldrich) (n = 5 M. cremasters of healthy mice, n = 4 M.
cremasters of HU mice, n = 5 M. cremasters of HU+CKD mice). Number of perivascular
leukocytes was blind analyzed at the core facility Bioimaging of the Biomedical Center with
a Leica DM2500 microscope, equipped with a 100x objective (Leica, 1.4NA, oil immersion)
and a Leica DMC2900 CMOS camera.
Figure 7: Schematic represents of the experimental setup of intravital microscopie of the cremaster
muscle.
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3.3 Assessment of mouse kidney injury and fibrosis
Serum blood urea nitrogen (BUN) and creatinine (DiaSys, Holzheim, Germany), and serum
UA (BioAssay Systems, Hayward, USA) levels were measured using commercially available
kits as per manufacturer’s protocol. Kidneys from mice were harvested after sacrifice. One
kidney was used for flow cytometric analysis and the other was divided into two equal parts.
One part was kept in RNA later solution at -80°C for RNA isolation and the second part fixed
in 4% formalin to be embedded in paraffin for histology analysis. Periodic acid-Schiff (PAS)
and Sirius red reagents were used to assess kidney injury on 2 μm thick kidney sections.
3.4 Measurement of cytokines via ELISA
Concentrations of mouse IL-6, CXCL-1 and IL-1β in air pouch extracts were measured using
the mouse ELISA kits for IL-6 and IL-1β (Ray Biotech, Norcross, USA) and CXCL-1
(EBiosciences, Germany) according to manufacturers’ protocols. The absorbance was
measured on a Multiskan EX reader (Thermo Electron Corporation, Germany). Briefly,
a) coat 96-well immune plate with diluted capture antibody, incubate overnight at 4°C.
b) wash plate 3 times with PBST, then incubate with assay diluent for 1 hour.
c) wash 3 times, add the standards, samples and sample diluent (blank) into each wells,
incubated at room temperature (RT) for 2 hours.
d) wash 5 times, add diluted secondary antibody, incubated at RT for 1 hour.
e) wash 5 times, add Avidin-HRP, incubated at RT for 1 hour.
f) wash 5-7 times, add 100 μl of substrate, incubated for 20-30 minutes in the dark.
g) add 50 μl of 2 M H2SO4.
h) measured at 450 nm (reference wavelength 620 nm) using a spectrophotometer
(TECAN-Genios Plus).
3.5 Clinical study procedures
The study included 10 patients with CKD (CKD, CKD stage G2-4; male/female: 6/4; mean
age: 57.13 ± 5.89 years), 18 patients with ESKD that were on hemodialysis (ESKD, G5D;
male/female: 11/7; mean age: 57.28 ± 3.74 years) and 15 healthy individuals without renal
impairment (healthy, CKD stage G0) (male/female: 7/8; mean age: 44.50 ± 4.84 years).
There was no significant difference in age between the groups. We excluded 8 patients due to
the intake of immunosuppressive drugs e.g. cyclosporine, and urate lowering drugs, e.g.
allopurinol, febuxostat (Figure 18). Blood was collected, centrifuged at 8000 rpm for 8
minutes and plasma transferred into 1.5 ml plastic Eppendorf tubes, and stored at -20°C until
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analysis. Plasma creatinine, BUN and UA levels were measured using the creatinine FS kit,
urea FS kit and the UA assay kit according to the protocol provided by the manufacturer. The
study to obtain whole blood samples from healthy volunteers and uremic patients was
approved by the local Ethical Review Board of the Medical Faculty at the Klinikum der
Universität München (369-15). Informed consent was obtained from all subjects prior to
inclusion in the study.
3.6 Human blood neutrophils and CD14+ monocytes isolation
Neutrophils were isolated from human healthy individuals and CKD/ESKD patients using
standard dextran sedimentation followed by Ficoll–Hypaque density centrifugation
procedures204. Briefly, the collected whole blood was mixed with 1.25% dextran at 1:1 and
after 10-20 minutes in 4 °C the red blood cells settled down, and the supernatants which
contain white blood cells (WBCs). The cells were washed with D-PBS, and the WBCs were
lysed with 10 ml cold distilled water for 20 seconds and the reaction was stopped using 4 ml
of 0.6 M potassium chloride (KCl) buffer. The cells were then washed with DPBS, re-
suspended in 4 ml DPBS and 4 ml Ficoll gradient solution added on the top. The cell solution
was centrifuged for 30 minutes at 1500 rpm at 4 °C without break. After centrifugation, the
peripheral blood mononuclear cells (PBMCs) layer in the middle and the neutrophil pellet at
the bottom of the tube were collected.
Human PBMCs were isolated from healthy individuals and CKD/ESKD patients and CD14+
monocytes purified by magnetic activated cell sorting (MACS) with human CD14
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany), according to manufacturer’s
protocol. Briefly, PBMCs were re-suspended in magnetic separation buffer and mixed with
CD14 microbeads. After 15 minutes of incubation at 4 °C, the cells were washed and re-
suspended in magnetic buffer, then cells suspension was applied onto the magnetic column,
which was already placed on a magnetic cell separator. After three times of washing, the
column was removed from the separator and 5 ml buffer added onto the column, the CD14+
monocytes were flushed out by firmly pushing the plunger.
3.7 Preparation of soluble uric acid
UA (Sigma-Aldrich, Taufkirchen, Germany) was solubilized in 4N NaOH. Afterwards the
pH was adjusted to 7.4 by adding 6N HCl and the UA stock solution (0.01M sUA) filtered
sterile using a 0.22 m filter. The concentration of sUA was examined by commercial UA
assay kit, then split and stored in -20 °C for further use.
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3.8 Human neutrophil extracellular traps formation and quantification
Neutrophils from healthy individuals and ESKD patients were pre-incubated with or without
10 mg/dl sUA for 1 hour prior to stimulation with PMA (25 nM; Sigma-Aldrich) or MSU
crystals (200 µg/ml) for an additional 3 hours. For indirect NET formation via soluble
mediators, supernatants from activated monocytes (as indicated above) were added to the
neutrophil culture for 3 hours. Afterwards, neutrophils were fixed with 4% paraformaldehyde
and NETs stained for citrullinated histone 3 (cit. histone H3, Cell Signaling, Danvers, MA),
neutrophil elastase (NE, Santa Cruz Biotechnology, Santa Cruz, CA) and DAPI as previously
described204. The % area of cit. histone H3 and NE and were quantified for NET formation
using ImageJ software. NETs were quantified in supernatants with the MPO-DNA sandwich
ELISA using an anti-DNA (Roche, Germany) and anti-human MPO antibody (AbD Serotec,
Raleigh, North Carolina), as previously described205, or with the PicoGreen dsDNA Assay
Kit (Fisher Scientific, Schwerte, Germany) according to manufacturer’s instruction.
3.9 Transwell migration assays
Migration assays were carried out in 24-well transwell plates using hanging chamber inserts
with 3-μm pore transwell filters (Sigma-Aldrich, Taufkirchen, Germany). Neutrophils (2×
105 cells/transwell) from healthy individuals or ESKD patients were isolated and pre-treated
with or without 0.6 mM sUA for 30 minutes, or 20% serum from healthy individuals, CKD
and ESKD patients (with or without 0.1 µg/ml rasburicase), and added in the upper chamber.
The chemoattractants N-formyl-methionyl-leucyl-phenylanine (fMLP) (50 ng/ml), human IL-
8 (100 ng/ml) or human IL-1β (250 ng/ml) (Immunotools, Friesoythe, Germany) were added
to RPMI media in the bottom chamber and incubated for 3 hours at 37°C and 5% CO2, as
shown in Figure 8. Total number of migrated neutrophils/µl in the bottom chamber was
quantified using AccuCheck counting beads (Thermo Fisher Scientific, München, Germany)
by flow cytometry (FACSCalibur, USA).
Figure 8: Schematic showing the transwell migration assay of human neutrophils.
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3.10 Human LFA-1 neutrophil activation assay
β2 integrin activation in neutrophils was assessed as previously described206. Briefly, isolated
human neutrophils from healthy blood donors (using Polymorphprep; AXIS-SHIELD PoC
AS) were incubated with sUA (0.6 mM) or carrier substance, respectively for 30 minutes at
37°C (in HBSS buffer, containing 0.1% of glucose, 1 mM CaCl2, 1 mM MgCl2, 0.25% of
BSA, and 10 mM HEPES (Sigma-Aldrich), pH7.4) and then stimulated for 5 minutes at 37°C
with CXCL8/IL-8 (0.1 mg/ml; Peprotech). Integrin activation was stopped by adding ice cold
FACS lysing solution (BD Bioscience). Fully activated β2 integrins were detected using
mAB24 antibodies (clone 24) and flow cytometry (Gallios, Beckman Coulter). Human
neutrophils were defined as CD15 (clone W6D3), CD66b (clone G10F5) double positive
cells. In addition to that, total surface expression levels of LFA-1 (clone HI111) and MAC-1
(αMβ2 integrin; CD11b/CD18; clone ICRF44; all Biolegend) were quantified. Flow cytometry
data was analyzed using Kaluza Flow analysis Software (Beckman Coulter).
3.11 Human monocyte stimulation assay
CD14+ monocytes were isolated and pretreated with 10 mg/dl sUA or 20% serum from CKD
or ESKD patients or healthy individuals in the presence of absence of rasburicase (0.1 µg/ml)
for 1 hour, and then stimulated either with 10 µg/ml LPS (Sigma-Aldrich, Taufkirchen,
Germany) or 500 µg/ml MSU crystals or left untreated (medium control). After one or four
hours, total monocyte mRNA was isolated for RT-PCR, or prepared for surface marker and
intracellular cytokine staining by flow cytometry, or supernatants collected for NET
formation assays.
After pretreatment with 10 mg/dl sUA or medium alone, CD14+ monocytes were stained with
the surface antibodies: anti-human CD162 (PSGL-1), anti-human CD49d (VLA-4a)
(BioLegend, Fell, Germany). For intracellular cytokine staining, CD14+ monocytes were
incubated with GolgiPlug for 15 minutes to avoid release of intracellular cytokines prior to
stimulation. Cells were then harvested, washed and resuspended in cell
fixation/permeabilization buffer for 15 minutes and washed in permwash buffer. Intracellular
antibodies for anti-human TNF-α and anti-human IL-6 (BioLegend, Fell, Germany) were
added for 40 minutes at 4°C. After incubation, cells were washed with PBS and reconstituted
in fresh wash buffer (0.1% BSA, 0.01% sodium azide in PBS). Flow cytometric analysis was
performed using the BD FACSCalibur and analyzed using the software FlowJo 8.7 (Tree Star
Inc., Ashland, OR).
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3.12 THP-1 cell culture and stimulation
Human monocytic leukemia THP-1 cell line was purchased from American Type Culture
Collection (ATCC) and grown in RPMI-1640 culture medium supplemented with 10% fetal
bovine serum (Biochrom, Berlin, Germany), 2 mM glutamine (Gibco, Invitrogen, Grand
Island, NY, USA), 1 mM sodium pyruvate, 10 mM HEPES, and 1% penicillin/streptomycin
(PAA Laboratories, Pasching, Austria). Cells were incubated at 37°C (with humidity) in 5%
CO2.
THP-1 cells were cultured in 6-well plates (Costar, Corning Incorporated, Corning, NY, USA)
at a cell density of 1×106 cells/well and pre-incubated with 0.6 mM sUA for 1 hour prior to
stimulation with 10 µg/ml LPS or 100 ng/ml TNF-α for another 4 hours. Cells were harvested
for RNA preparation and real-time quantitative PCR (NFKB-p50, NLRP3, ASC, IL-6, TNF-
alpha), and culture supernatants were collected and stored at -80°C until analysis.
3.13 Small interfering RNA (siRNA) transfection
SLC2A9 (GLUT9) and control siRNAs were purchased from RIBOXX (Radebeul, Germany).
THP-1 cells (1 × 106 /well) were transiently transfected with 120 nM of siRNA control and
SLC2A9 using the NeonTM transfection system (Thermo Fisher Scientific, Germany) with the
following electroporation parameters: Pulse voltage 700 v, Pulse width 40 ms and Pulse
number 4, plain RPMI medium was changed with complete RPMI medium (10% of FBS)
after 4 hours post transfection. 48 hours post transfection, the cells were pre-incubated with
10 mg/dl sUA for 1 hour prior to stimulation with 10 µg/ml LPS or 100 ng/ml TNF-α for
another 4 hours.
3.14 Uric acid uptake assay in THP-1 cells
Human monocytic leukemia THP-1 cells were pretreated with or without 10 mg/dl sUA for 1
hour in serum-free RPMI media and then treated with 10 µg/ml LPS or 100 ng/ml TNF-α for
another 4 hours. The culture supernatants were collected after 4 hours, and the cells harvested,
washed with PBS and digested. The concentration of sUA in cell culture supernatants and
cytosol were measured by commercial UA assay kit and the intracellular sUA uptake rate
was determined by adjusting the UA levels to cell number (1x106 cells) in each sample.
3.15 RNA analysis
The RNA extraction kit from Qiagen (Düsseldorf, Germany) was used to isolate total RNA
from mouse kidneys (n = 5 per group) or human blood monocytes as well as THP-1 cells
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following the manufacturer’s instructions. RNA quality was assessed using a Nano drop
(PEQLAB Biotechnology GmbH, Erlangen, Germany) and agarose gels before being
transcribed into cDNA using reverse transcriptase (Superscript II) (Invitrogen, Carlsbad, CA).
To get the cDNA, the master mix that contained RNA (Table1) was incubated at 420C for 1
hour and 30 minutes, then 900C for 5 minutes. Real-time RT-PCR was performed using
SYBR Green PCR master mix (Table 2) and analyzed with a Light Cycler 480 (Roche,
Mannheim, Germany). All gene expression values were normalized using 18s rRNA or
GAPDH as a housekeeping genes. All mouse and human primers used for amplification were
purchased from Metabion (Martinsried, Germany) and are listed in Table 3.
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Table 1: RNA to cDNA master mix
Reagent Volume (μl)
RNA+ DEPC treated water 30 (contain 2 ug RNA)
5x buffer 9
25 mM dNTP 1
0.1 M DTT 2
Lin Acrylamid 0.5
40U/ μl RNAsin 1
Hexanucleotide 0.5
Superscript 1
Table 2: the RT-PCR master mix
Reagent Volume (μl)
SYBR green master mix 10
Forward primer 0.6
Reverse primer 0.6
Taq polymerase 0.16
DEPC treated water 6.64
cDNA (1:10) 2
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Table: 3. Oligonucleotide primer sequences used in the study
Mouse Genes Primer sequences
KIM-1 Forward 5‘-TCAGCTCGGGAATGCACAA-3‘Reverse 5‘-TGGTTGCCTTCCGTGTCTCT-3‘
Tnfα Forward 5‘-CCACCACGCTCTTCTGTCTAC-3‘Reverse 5‘-AGGGTCTGGGCCATAGAACT-3‘
Col1α-1 Forward 5‘-ACATGTTCAGCTTTGTGGACC-3‘Reverse 5‘-TAGGCCATTGTGTATGCAGC-3‘
Fibronectin 1 Forward 5‘-GGAGTGGCACTGTCAACCTC-3‘Reverse 5‘-ACTGGATGGGGTGGGAAT-3‘
18s RNA Forward 5‘-GCAATTATTCCCCATGAACG-3‘Reverse 5‘-AGGGCCTCACTAAACCATCC-3‘
Human Genes Primer sequences
NLRP3 Forward 5‘-CTTCTCTGATGAGGCCCAAG-3‘Reverse 5‘-GCAGCAAACTGGAAAGGAAG-3‘
ASC Forward 5‘-AGCTCACCGCTAACGTGCTGC-3‘Reverse 5‘-GCTTGGCTGCCGACTGAGGAG-3‘
IL-6 Forward 5‘-ACAAATTCGGTACATCCTC-3‘Reverse 5‘-GCAGAATGAGATGAGTTGT-3‘
TNF-alpha Forward 5‘-CTTCTCCTTCCTGATCGTGG-3‘Reverse 5‘-GCTGGTTATCTCTCAGCTCCA-3‘
NFKB-p50 Forward 5‘-GCAGCACTACTTCTTGACCACC-3‘Reverse 5‘-TCTGCTCCTGAGCATTGACGTC-3‘
IL-12p40 Forward 5‘-GACATTCTGCGTTCAGGTCCAG-3‘Reverse 5‘-CATTTTTGCGGCAGATGACCGTG-3‘
CCL2 Forward 5‘-TAGATACAGAGACTTGGGGAAATTGC-3‘Reverse 5‘-TGATTCTTGCAAAGACCCTCAAAAC-3‘
IL-10 Forward 5‘-CTGTGAAAACAAGAGCAAGGC-3‘Reverse 5‘-GAAGCTTCTGTTGGCTCCC-3‘
SLC2A9 (GLUT9) Forward 5‘-GCTCTTGGAGAAGCACAACGAG-3‘Reverse 5‘-ACACCAGGCGGATGCTCCTCT-3‘
SLC22A12 (URAT-1) Forward 5‘-TTGATTGGCAGGAGGTGA CC-3‘Reverse 5‘-GGTTAAGTGGAGTCGGTCAG-3‘
SLC22A6 (OAT1) Forward 5‘-CCACCTCTTCCTCTGCCTCTCCAT-3‘Reverse 5‘-GTCTGTTTCCCTTTCCTGCTCTCC-3‘
SLC22A11 (OAT4) Forward 5‘-CAGACCAAGCACTTCAGGAGCT-3‘Reverse 5‘-TCCTTCACGCTGGACATCAGCA-3‘
SLC22A13 (OAT10) Forward 5‘-TTTCCGCAACTGGAGGCTCCTT-3‘Reverse 5‘-GTTGTATCGCCTCGTCCATCCT-3‘
GAPDH Forward 5‘-GTCTCCTCTGACTTCAACAGCG-3‘Reverse 5‘-ACCACCCTGTTGCTGTAGCCAA-3‘
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3.16 Flow cytometry
3.16.1 Flow cytometric analysis of murine samples
Blood and air pouch fluids were collected from mice. Blood was collected in tubes containing
EDTA and red blood cells lysed using ammonium chloride for 10 minutes at room
temperature. White blood cells were washed in PBS buffer, centrifuged and reconstituted in
wash buffer (0.1% BSA, 0.01% sodium azide in PBS). After blocking the FcR with anti-
mouse CD16/32 (2.4G2) for 5 minutes, cells were stained with the surface antibodies FITC
anti-mouse Ly6G, PE anti-mouse Ly6C, PE/Cy5 anti-mouse CD45 and APC anti-mouse
CD11b (all antibodies obtained from BioLegend, Fell, Germany) for 30 minutes. After
staining, cells were washed with wash buffer and stored at 4 °C for flow cytometric analysis.
Air pouch fluid was harvested by injecting 1 ml cold PBS into the air pouch. Air pouch
extracts were retrieved with a 1 ml syringe and centrifuged at 1200 rpm for 5 minutes.
Supernatants were collected and stored at -20 °C for further cytokine and chemokine analysis
by Enzyme-linked immune-sorbent assay (ELISA). Air pouch extracts were suspended in
wash buffer and FcR blocked for 5 minutes before staining with the surface antibodies FITC
anti-mouse Ly6G, PE anti-mouse Ly6C, PE/Cy5 anti-mouse CD45 and APC anti-mouse
CD11b for 30 minutes. After incubation, cells were washed with PBS and reconstituted in 1
ml fresh wash buffer. Flow cytometric analysis was performed using the BD FACSCanto II
and data analyzed with the software. For determining the number of cells/μl, Invitrogen
AccuCheck counting beads were used and the absolute cell counts calculated according to
manufacturer’s instruction.
3.16.2 Flow cytometric analysis of human samples
Neutrophils were identified as CD15+CD11b+CD66b+ by flow cytometry and had a purity of
approximately 99% (Figure 19A). The antibodies used were FITC anti-human CD11b
(BioLegend, Fell, Germany), PE anti-human CD66b, APC and anti-human CD15 (both from
eBiosciences, Germany) (Figure 19A). Neutrophils were suspended in RPMI (0.5*106 cells
per 300 µL or 1*106 cells/ml) and seeded onto eight-well microslides (Ibidi, Martinsried,
Germany) or 24-well plates in a 5% carbon dioxide atmosphere at 37 °C for 30 minutes
before stimulation.
Human CD14+ monocytes were identified using the antibodies FITC anti-human CD14, PE
anti-human CD15 and APC anti-human CD16 by flow cytometry with a purity of 88%
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(Figure 22A). Monocytes were suspended in RPMI (1*106 cells/ml) and seeded onto 24-well
plates in a 5% carbon dioxide atmosphere at 37 °C for 30 minutes before stimulation.
3.17 Statistical analysis
Prior to the application of any other statistical methods, the Shapiro-Wilk Normal distribution
test, the Levene homoscedasticity test and the Grubb outlier test applied to the data set.
Student’s t-test was only used for the comparison of two normally distributed datasets.
Alternatively, in the case of two non-normally distributed datasets, the Wilcoxon-Mann-
Whitney test was used.
For more than two datasets, the normally distributed and homoscedastic datasets were
evaluated by using one-way analysis of variance (ANOVA) with Tukey’s post-test. In the
case of heteroscedasticity, the post-hoc Games Howell test was used. When using two
parameters with multiple groups, two-way ANOVA with Bonferroni’s comparison post-hoc
test was carried out.
Statistical analyses were performed using GraphPad Prism 7 (CA, USA). Unless otherwise
indicated, data are presented as mean values ± standard error of the mean (SEM). Differences
were considered significant if p<0.05; non-significant differences (ns) are indicated
accordingly. Sample sizes were indicated in each corresponding figure legend.
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4 Results
4.1 A mouse model of hyperuricemia with or without chronic kidney disease
Recently, the glucose transporter family member GLUT9 (encoded by SLC2A9 gene) was
reported to be a UA transporter63. In human and mice, GLUT9 is mainly expressed in
proximal renal tubular cells and responsible for reabsorbing UA from the urine into the blood.
However, in mice, SLC2A9 is also expressed in the basolateral membrane of hepatocytes and
mediates the UA uptake in hepatic cells, which can be degraded via the enzyme uricase into
the more water soluble allantoin, a metabolite that is freely excreted by the urine207. To
investigate the impact of HU and CKD on sterile inflammation, we used a mouse model of
HU with or without CKD by inducing liver-specific Glut9 deficiency with tamoxifen in Alb-
creERT2;Glut9lox/lox mice207 and as well as control Glut9lox/lox mice. Both mouse strains were
either fed a high-fat diet enriched with the purine inosine, a precursor of UA, or a standard
chow diet with inosine for 22 days.
Compared to Glut9lox/lox control mice (healthy), the serum UA levels significantly increased
in all Alb-creERT2;Glut9lox/lox mice exposed to both diets indicating that the Alb-
creERT2;Glut9lox/lox mice developed HU, similar to serum UA levels observed in humans
(Figure 9A). However, only the Alb-creERT2;Glut9lox/lox mice on a high-fat diet had elevated
blood urea nitrogen (BUN) and creatinine levels compared to the Alb-creERT2;Glut9lox/lox
mice on chow+inosine diet or Glut9lox/lox control mice (Figure 9B, C).
Furthermore, PAS staining showed tubular injury and diffused tubular atrophy in HU+CKD
mice but not in healthy and HU mice (Figure 9D). This was confirmed by an increased renal
mRNA expression of the kidney injury marker KIM-1 in mice with HU+CKD (Figure 9E).
Intrarenal mRNA expression of the inflammatory marker Tnfα revealed that the HU+CKD
mice had increased Tnfα mRNA expression levels compared to the other two groups (Figure
9F). This was in line with a significant higher number of infiltrating CD45+ cells (Figure 9G)
and neutrophils (Figure 9H) into the kidneys of HU+CKD mice, which implied that
hyperuricemic mice with CKD showed increased tubular injury and inflammation associated
with an impaired renal function compared to hyperuricemic mice without CKD or healthy
mice.
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Figure 9: A mouse model of HU with or without CKD. Alb-creERT2;Glut9lox/lox mice and
Glut9lox/lox control mice were injected intraperitoneal with tamoxifen. Both groups were fed either a
high-fat diet enriched with inosine or a standard chow diet with inosine for 22 days. (A to C) Serum
uric acid (UA) (A), blood urea nitrogen (BUN) (B) and creatinine (C) levels of Glut9lox/lox mice with
chow diet and inosine (healthy), Alb-creERT2;Glut9lox/lox mice with chow diet (HU) and high-fat diet
with inosine (HU+CKD) on day 22 (n = 7 mice per group). (D) Periodic acid-Schiff (PAS) staining
(original magnification 100x). (E to F) Intrarenal mRNA expression levels of kidney injury marker
KIM-1 (E) and inflammation marker Tnfα (F) (n = 4-8 per group, one-way ANOVA). (G to H) Flow
cytometric analysis of infiltrating CD45+ leukocytes (G) and neutrophils (H) in kidneys with absolute
numbers (n = 4-8 per group, one-way ANOVA). Data are mean ± SEM. * p<0.05; ** p<0.01; ***
p<0.001; ns = not significant.
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CKD is characterized by a gradual loss of kidney function associated with glomerulosclerosis,
vascular sclerosis and tubulointerstitial fibrosis. Sirius Red staining, a specific fibrosis
staining for collagen type I and III, showed that only hyperuricemic mice with CKD showed
interstitial fibrosis compared to healthy and hyperuricemic mice on kidney sections (Figure
10A). Consist with the fibrosis staining mRNA levels of the kidney fibrosis marker Col1α-1
and Fibronectin 1 were also increased in the HU+CKD mice (Figure 10B and C). Taken
together, the data show a mouse model of HU with or without CKD.
Figure 10: Alb-creERT2;Glut9lox/lox mice on high-fat diet with inosine developed kidney fibrosis.
Alb-creERT2;Glut9lox/lox mice and Glut9lox/lox control mice were injected intraperitoneal with
tamoxifen. Both groups were fed either a high-fat diet enriched with inosine or a standard chow diet
with inosine for 22 days. (A) Sirius red staining of Glut9lox/lox control mice with chow diet and inosine
(healthy), Alb-creERT2;Glut9lox/lox mice with chow diet (HU) and high-fat diet with inosine
(HU+CKD) on day 22. (original magnification 100x); (B to C) Intrarenal mRNA expression level of
the kidney fibrosis marker Col1α-1 (B) and Fibronectin 1 (C) (n = 5-8 per group, one-way ANOVA).
Data are mean ± SEM. * p<0.05; ** p<0.01; *** p<0.001; ns = not significant.
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4.2 Hyperuricemia contributes to CKD-related suppression of acute gouty
inflammation
The first of our three objectives was to investigate whether HU has immunomodulatory
effects on the acute inflammatory response in vivo during experimental gouty arthritis in
CKD, e.g. the release of inflammatory mediators, the leukocyte rolling, adhesion and
extravasation induced by MSU crystals. In addition, rasburicase treatment in HU mice with
CKD was further tested to determine the putative contribution of HU during gout.
4.2.1 Hyperuricemia and CKD synergistically attenuate MSU crystal-induced gouty
arthritis-like sterile inflammation
To mimic acute gouty arthritis162, twice sterile air (on day17 and day 19) was injected into
the intra-scapular area of the back of all three groups mice (HU+CKD, HU and healthy). The
pouch primarily consists of macrophage- and fibroblast-like cells, which is similar to the
synovial cavity208. Afterwards, 5mg MSU crystals or vehicle (on day 21) was injected into
the preexisting air pouch in all three groups of mice. Twelve hours later after MSU injection,
the air pouch lavage was collected. The numbers of infiltrated leukocytes were analyzed by
flow cytometry and the levels of cytokines examined by ELISA.
In all three groups of mice, MSU crystal aggregates were observed as shown in Figure 11A.
Flow cytometry analysis revealed a significant increase in the number of infiltrating CD45+
cells, neutrophils, and monocytes in all three groups of mice that were injected with MSU
crystals compared to vehicle (Figure 11B to D). However, compared to healthy mice, the
number of infiltrating CD45+ cells, neutrophils and monocytes into the air pouch after MSU
crystal injection significantly decreased in HU mice (Figure 11B to D). This effect of
impaired leukocyte infiltration was even more pronounced in HU+CKD mice (Figure 11B to
D). The findings suggested that HU and CKD suppressed MSU crystal-induced leukocyte
recruitment.
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Figure 11: Hyperuricemia and CKD attenuate MSU crystal-induced leukocyte recruitment.
Alb-creERT2;Glut9lox/lox mice and Glut9lox/lox control mice were injected with tamoxifen. Both groups
were fed either a high-fat diet enriched with inosine or a standard chow diet with inosine for 22 days.
On day 21, mice received a s.c. injection of MSU crystals or vehicle into a pre-existing air pouch, and
sacrificed 12 hours later. (A) Representative images of vehicle and MSU crystals injected into the air
pouch. (B to D) Numbers of CD45+ cells (B), neutrophils (C) and monocytes (D) in air pouch per µl
from mice with or without MSU crystals determined by flow cytometry (n = 3-6 per group). Data are
mean ± SEM. * p<0.05; ** p<0.01; *** p<0.001; ns = not significant by two-way ANOVA.
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An acute gout attack is characterized by the infiltration of leukocytes and the production of
inflammatory mediators including pro-inflammatory cytokines and chemokines172. To test the
effect of HU and CKD on the inflammatory mediators also in this model, the levels of the
pro-inflammatory cytokines IL-1β and IL-6, as well as the chemoattractant CXCL-1 levels in
the air pouch fluid were measured. As shown in Figure 12, MSU crystal injection
significantly increased the levels of IL-1β (Figure 12A), IL-6 (Figure 12B) and CXCL-1
(Figure 12C) in all three groups of mice compared to vehicle-treated mice. Consist with the
flow cytometry results, the cytokine and chemokine levels were lower in hyperuricemic mice
compared to healthy mice. This difference was even more significant in mice with HU and
CKD (Figure 12A to C). Together, HU and CKD suppressed MSU crystal-induced leukocyte
recruitment and attenuated gouty arthritis-like sterile inflammation. However, how exactly
HU impairs leukocyte recruitment to the site of still needs to be explored in more detail.
Fig. 12: Hyperuricemia and CKD attenuate MSU crystal induced inflammatory cytokines and
chemokines production. Alb-creERT2;Glut9lox/lox mice and Glut9lox/lox control mice were injected
with tamoxifen. Both groups were fed either a high-fat diet enriched with inosine or a standard chow
diet with inosine for 22 days. On day 21, mice received a s.c. injection of MSU crystals or vehicle
into a pre-existing air pouch, and sacrificed 12 hours later. (A to C) Concentrations of IL-1β (A), IL-6
(B) and CXCL-1 (C) measured in the air pouch fluid via ELISA (n = 3-6 per group). Data are mean ±
SEM. * p<0.05; ** p<0.01; *** p<0.001; ns = not significant by two-way ANOVA.
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4.2.2 Rasburicase treatment reversed the suppressive effect of HU
As demonstrated in section 4.2.1, HU and CKD suppressed MSU crystal-induced leukocyte
recruitment and attenuated the inflammatory response. To test the putative contribution of
HU during gout, the HU+CKD mice were treated with rasburicase or vehicle prior to MSU
crystal injection (details in methods 3.2.3 and Figure 6). Rasburicase is a FDA-approved and
commercially available recombinant urate oxidase that can degraded UA into allantoin
resulting in lower serum UA levels in humans and mice70. Rasburicase treatment significantly
decreased the serum UA levels from 10 mg/dl to 6 mg/dl compared to the vehicle-treated
group (Figure 13A) without affecting the BUN levels (Figure 13B), indicating that
rasburicase treatment did not improve kidney function. Importantly, rasburicase did not alter
the MSU crystal deposition in the air pouch (Figure 13C).
Flow cytometry analysis showed that rasburicase treatment significantly increased the
number of infiltrating CD45+ cells and neutrophils after MSU crystal injection into the air
pouch, while rasburicase itself did not influence the number of leukocytes in the vehicle-
treated group (Figure 13D and E). In addition, the levels of IL-1β, IL-6, and CXCL-1
increased after rasburicase treatment compared to vehicle-treated HU+CKD mice upon MSU
crystal injection (Figure 13F to H). These findings suggested that HU mediated in part the
immunosuppressive effect of CKD during acute gouty arthritis.
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Figure 13: Rasburicase treatment increases MSU crystal-induced leukocyte recruitment and
inflammation in mice with HU and CKD. Alb-creERT2;Glut9lox/lox mice were injected with
tamoxifen and placed on a high-fat diet with inosine (HU+CKD) for 22 days. Mice received vehicle
or rasburicase treatment prior to injection of vehicle or MSU crystals into a preexisting air pouch, and
sacrificed after 12 hours. (A to B) Serum UA (A) and BUN (B) levels of HU+CKD mice with
rasburicase or vehicle treatment (n = 5 per group, Student’s t-test). (C) Representative images of
MSU crystal injection into the air pouch with or without rasburicase. (D to E) Flow cytometry
analysis of infiltrating CD45+ cells (D) and neutrophils (E) into the air pouch from mice with or
without MSU crystals and/or rasburicase treatment (absolute numbers) (n = 4-6 per group). (F to H)
Concentrations of IL-1β (F), IL-6 (G) and CXCL-1 (H) from air pouch fluid measured via ELISA (n
= 4-6 per group). Data are mean ± SEM. * p<0.05; ** p<0.01; *** p<0.001; ns = not significant by
two-way ANOVA.
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4.3 Hyperuricemia and CKD synergistically attenuate MSU-crystal-induced
leukocyte rolling, adhesion, and extravasation in vivo
The recruitment of neutrophils from the circulation to the site of inflammation occurs in four
steps: the rolling, adhesion, crawling, and transmigration209. In the previous section we found
that HU and CKD contribute to impaired neutrophil migation during acute gouty
inflammation. To investigate the effect of HU and CKD on the different steps of the
leukocyte recruitment cascade, we performed intravital microscopy of postcapillary venules
in the cremaster muscles of mice from all three groups 4 hours after intramuscular injection
of MSU (500 g) crystals (see methods and materials, section 2.2.4). Intravital microscopy of
postcapillary venules of the cremaster muscle is a widely used method for investigating
leukocyte migration in living mice210.
As shown in Table 1, microvascular hemodynamic parameters including vessel diameter
(µm), center line velocity (µm/s) and shear stress rate (s-1) were identical in all three groups
of mice. We choose postcapillary venules with a diameter between 30-40 µm, because the red
blood cells were easier to distinguish from leukocytes by their nuclei. The microcirculatory
conditions, such as the blood flow velocity and the shear rate, normally do not have much
difference.
Table 4: Hemodynamic parameters of the cremaster muscle.
Descriptive Data Healthy HU HU+CKD P value
n (mice) 3 4 4
n (vessels) 13 23 22
Diameter (µm) 32±2 31±1 32±1 ns (p=0.7744)
Centerline velocity (µm/s) 1577±167 1787±114 1745±149 ns (p=0.6192)
Shear rate (s-1) 1280±167 1438±81 1351±103 ns (p=0.6192)
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Next, we analyzed the functional parameters related to leukocytes migration. The rolling
leukocyte flux fraction, which indicates the percentage of leukocytes that travel across each
micro-vessel211, was higher in vessels of HU and HU+CKD mice compared to vessels of
healthy mice (Figure 14A). In addition, the mean rolling velocity of the interacting
leukocytes (Figure 14B) as well as the cumulative frequency (Figure 14C) was significantly
increased in vessels of HU mice and even higher in HU+CKD mice. Representative images
are shown in Figure 14D.
In contrast, HU significantly reduced the number of adherent cells/mm2, an effect that was
even stronger in HU+CKD mice (Figure 14E), indicating that HU mainly affects leukocytes
in their transition from rolling into firm arrest during the interaction with endothelial cells.
Because extravasation is a downstream event of leukocyte adhesion, we also quantified the
number of perivascular leukocytes on whole mount Giemsa-stained cremaster muscles.
Consistent with the reduced number of adherent leukocytes, HU also significantly decreased
the number of perivascular leukocytes, which further decreased in HU+CKD mice (Figure
14F). Differential cell counts displayed that the majority of perivascular cells were
neutrophils, and other cells including monocytes and eosinophil (Figure 14 G). These
findings demonstrated that HU and CKD synergistically modulate leukocyte rolling, adhesion,
and extravasation towards the site of MSU crystal-induced inflammation.
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Figure 14: Decreased leukocyte adhesion and extravasation in MSU crystal-stimulated
cremaster muscle venules in hyperuricemic mice with or without CKD. Alb-creERT2;Glut9lox/lox
and Glut9lox/lox control mice were injected with tamoxifen and placed on a chow or high-fat diet with
inosine (n = 3-4 mice per group). After 22 days, mice were injected intrascrotal with MSU crystals
(500 μg per mouse) for 4 hours and intravital microscopy carried out. (A to C) Rolling flux fraction
(A), rolling velocity (B), and cumulative frequency (C) (n = 13 venules of healthy mice, n = 23
venules of HU mice, n = 22 venules of HU+CKD mice). (D) Representative images of venules of the
cremaster muscles from all three groups (indicated by white dotted lines). V=vessels,
ET=extravascular tissue. (E to G) Quantification of the total number of adherent leukocytes/mm2 (E),
the total number of perivascular leukocytes/mm2 (F) on the microvessel wall surface, and distribution
of extravasated neutrophils and other cell subsets (G) (n = 10-13 vessels). Data are mean ± SEM. *
p<0.05; ** p<0.01; *** p<0.001; ns = not significant by one-way ANOVA.
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4.4 Soluble UA inhibits human neutrophil activation, β2 integrin expression
and transmigration in vitro
The ability of immune cells to migrate through the endothelium to the site of inflammation
depends on selectins, chemokine receptors, adhesion molecules and β2 integrins such as
(CD11/CD18)212. The β2 integrin is well studied in the field of neutrophil recruitment and its
dysfunction can cause impaired neutrophil migration213. As shown in section 4.3, HU and
CKD modulate leukocyte rolling, adhesion, and extravasation in a mouse model of MSU
crystal-induced inflammation.
4.4.1 Soluble UA inhibits β2 integrin expression on healthy human neutrophils
To study whether sUA can also affect adhesion molecule expression and β2 integrin
activation in human neutrophils will be investigated in this section, blood neutrophils from
healthy individuals were isolated and stimulated for 30 minutes with 0.6 mM sUA or vehicle
(control) followed by 5 minutes stimulation with IL-8 to activate β2 integrins and adhesion
molecules in vitro. The total surface expression of LFA-1 and MAC-1 subunits of β2 integrin
was quantified by flow cytometry.
While activation of healthy neutrophils with IL-8 alone did not affect total LFA-1 expression,
pre-incubation with sUA significantly reduced the total amount of LFA-1 as compared to
control (Figure 15A). This effect could not be reversed by additional IL-8 stimulation (Figure
15A). Soluble UA stimulation also showed a trend towards reduced total MAC-1 expression
(Figure 15B), although this was not significant. Compared to vehicle or sUA alone, the total
amount of MAC-1 expression significantly increased upon IL-8 stimulation (Figure 15B).
Nevertheless, the presence of sUA reduced MAC-1 expression in IL-8-activated neutrophils
(Figure 15B).
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Fig. 15: Soluble UA affects β2 integrin expression levels on neutrophils. Human neutrophils were
isolated from healthy individuals and pre-incubated with or without 0.6mM sUA for 30 minutes prior
to stimulation with human IL-8. (A to B) The expression levels of LFA-1 (A) and MAC-1 (B) shown
as mean fluorescence intensity (MFI) relative to isotype control (n = 6-7) were quantified by flow
cytometric analysis. Data are mean ± SEM and values are representative of two independent
experiments. * p<0.05; ** p<0.01; *** p<0.001; ns = not significant by one-way ANOVA.
4.4.2 Soluble UA inhibits β2 integrin activation on healthy human neutrophils
The signaling cascade through β2 integrin on leukocytes can be distinguished in three
different conformation stages, as illustrated in Figure 16A. First, a bent form (V shape) with
the ligand-binding head (I domain) is close to the membrane, which represents inactive
integrin. Second, an extended form in a ‘switchblade-like’ motion with the ligand-binding
head away from the membrane represents intermediate integrin affinity. Third, the extended
form is in an open conformation and represents high integrin affinity212. Upon close
interaction between the β-subunit (ligand-binding I domain) and the α-subunit (the extended
form), the activation status of leukocytes can be tested using the high affinity β2 integrin
activation marker mAB24. Stimulation with IL-8 induced β2 integrin activation as indicated
by increased mAB24 binding and MFI compared to medium (Figure 16B and C). Consistent
with the previous findings, sUA also reduced mAB24 expression in IL-8-activated
neutrophils, indicating that sUA impaired β2 integrin activation (Figure 16C).
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Fig. 16: Soluble UA affects β2 integrin activation on neutrophils. Human neutrophils were isolated
from healthy individuals and pre-incubated with or without 0.6mM sUA for 30 minutes prior to
stimulation with human IL-8. (A) Schematic of three β2 integrin conformations that reflect the
different stages of cell activation: 1. The bent form – inactive; 2. The extended from with a closed
ligand-binding head of intermediate affinity; 3. The extended form enabling the ligand-binding for
mAB24 with high affinity (adopted from Evans, et al212). (B and C) mAB24 binding illustrated as
histogram (B) and the expression levels of mAB24 (C) determined by flow cytometry (n = 6-7). Data
are mean ± SEM. Data are mean ± SEM and values are representative of two independent
experiments. * p<0.05; ** p<0.01; *** p<0.001; ns = not significant by one-way ANOVA.
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4.4.3 Soluble UA prevents healthy human neutrophil migration in transwell assay
Soluble UA inhibits β2 integrin expression and activation in healthy human neutrophils. To
test the effect of sUA on neutrophil sensing chemokine gradients, neutrophils from healthy
individuals were pre-incubated with vehicle (control) or sUA for 30 minutes and allowed to
migrate across a transwell filter in the presence or absence of different chemokines and
cytokines for 3 hours. As shown in Figure 17A to C, the presence of sUA attenuated the
migratory capability of neutrophils towards IL-8, IL-1β, and fMLP. However, sUA itself did
not alter the ability of human neutrophils to migrate compared to medium control alone
(Figure 17 A to C). These findings demonstrate that sUA impaired the activation status and
therefore the migratory ability of neutrophils along chemokine gradients, which might be an
explanation for the impaired leukocyte recruitment observed in vivo (section 4.2 and 4.3).
Figure 17: Soluble UA prevents healthy human neutrophil migration in transwell assay. (A to C)
Transwell migration assays were carried out and the number of neutrophils per µl that migrated
towards the chemoattractants human IL-8 (A), human IL-1β (B) and fMLP (C) was determined after 3
hours by flow cytometry (n = 6-12). Data are mean ± SEM and values are the pooled from three
independent experiments. * p<0.05; ** p<0.01; *** p<0.001; ns = not significant by one-way
ANOVA.
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4.5 Hyperuricemia in uremic patients suppresses neutrophil migration
Neutrophils from uremic patients were reported to have a reduced chemotactic activity214 and
a variety of uremic toxins may contribute to this process (see introduction section 1.1.4). It
has shown in section 4.4 that sUA inhibits β2 integrin expression and activation in healthy
human neutrophils. To investigate the role of HU on the functional properties of neutrophils
from uremic patients, neutrophils were isolated from patients with different stages of CKD,
i.e. CKD stage 2-4 (CKD) and CKD stage 5 on dialysis (ESKD) as well as healthy
individuals.
4.5.1 Study design, clinical, and demographical characteristics
In this study, 51 patients were included and 8 of them were excluded due to the intake of
immunosuppressive drugs e.g. cyclosporine, and urate lowering drugs, e.g. allopurinol and/or
febuxostat. The 43 patients included were then divided into three groups: 10 patients with
CKD (CKD stage G2-4; male/female: 6/4; mean age: 57.13 ± 5.89 years), 18 patients with
ESKD that were on dialysis (ESKD, stage G5D; male/female: 11/7; mean age: 57.28 ± 3.74
years) and 15 healthy individuals without renal impairment (healthy, CKD stage 0)
(male/female: 7/8; mean age: 44.50 ± 4.84 years), as illustrated in Figure 18.
There was no significant difference in age between the three groups (Table 5). Plasma urea,
creatinine and UA levels were significantly higher in patients with CKD and ESKD
compared to healthy subjects (Table 5). The renal pathologies of the uremic patients were
diverse and included: hypertensive nephritis, diabetic kidney disease, minimal change disease,
microscopic polyangiitis, proteinuria, hyperaldosteronism, and polycystic kidney disease for
CKD patients, and diabetic kidney disease, hypertensive nephritis, IgA nephropathy, lupus
nephritis with focal segmental glomerulosclerosis (FSGS), membranous glomerulonephritis,
myeloma kidney disease, and contrast-induced nephropathy for ESKD patients (Table 6).
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Fig. 18: Schematic of study design. Out of 51 individuals, 8 patients were excluded due to the intake
of immunosuppressive drugs e.g. cyclosporine, and urate lowering drugs e.g. allopurinol, febuxostat.
Of the remaining, 10 patients represented with CKD (CKD stage G2-4), 18 patients with ESKD that
were on dialysis (CKD stage G5) and 15 healthy individuals without any renal pathologies (healthy,
CKD stage G0).
Table 5: Clinical and demographic characteristics.
Descriptive Data Healthyn=15
CKD
n=10
ESKD
n=18
Age (years) MeanP
44.50 ± 4.84 57.13 ± 5.89
0.120
57.28 ± 3.74
0.061
Gender MaleFemale
7
8
6
4
11
7
Plasma urea (mg/dl) MeanP
30.28 ± 3.83 59.12 ± 8.59
0.01
111.5 ± 8.07
0.001
Plasma creatinine (mg/dl) MeanP
1.51 ± 0.09 2.57 ± 0.46
0.426
9.25 ± 0.62
0.001
Plasma uric acid (mg/dl) MeanP
4.27 ± 0.26 8.93 ± 0.46
0.001
10.25 ± 0.55
0.001
Table 6: Main human pathological diagnoses.
Descriptive Data Healthy CKD ESKD
Kidney pathology None Hypertensive nephritis,
Diabetic kidney disease,
Minimal change disease,
Microscopic polyangiitis,
Proteinuria,
Hyperaldosteronism,
Polycystic kidney disease
Diabetic kidney disease,
Hypertensive nephritis,
IgA nephropathy,
Lupus nephritis with FSGS,
Membranous glomerulonephritis,
Myelom kidney disease,
Contrast-induced nephropathy
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4.5.2 Neutrophil number does not differ between uremic patients and healthy controls
To investigate the effect of HU on the functional properties of neutrophils from uremia
patients, neutrophils were isolated from healthy individuals, CKD and ESKD patients (see
methods and materials for the isolation process). Neutrophils were identified as
CD15+CD11b+CD66b+ by flow cytometry (see gating strategy) and had a purity of
approximately 99% (Figure 19A). Neutrophil counts revealed no significant difference
between CKD and ESKD patients compared with healthy individuals (Figure 19B).
Figure 19: No difference in number of neutrophils between uremic patients and healthy controls.
(A) Human neutrophils were isolated (see methods and materials) and identified as
CD15+CD11b+CD66b+ by flow cytometry with a purity of approximately 99%. (B) The number of
isolated neutrophils per ml from CKD and ESKD patients as well as healthy individuals. Data are
mean ± SEM (healthy, n = 15; CKD, n = 10; ESKD, n = 18; one-way ANOVA); ns = not significant.
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4.5.3 Hyperuricemia in uremic patients suppresses neutrophil migration
Neutrophils from healthy individuals showed decreased β2 integrin expression and activation
after treatment with sUA (see section 4.4). To investigate the role of HU on the functional
properties of neutrophils from uremia patients, the surface marker expression of L-selectin
(CD62L) and αM subunit of β2 integrin (MAC-1) were determined by flow cytometry. The
data revealed that neutrophils from ESKD patients showed significantly lower surface
expression of CD62L and MAC-1 compared to neutrophils from healthy controls (Figure
20A and B). Next, the ability of sUA-stimulated neutrophils to sense chemokines were
quantified by performing transwell migration assays as before. Compared to neutrophils from
healthy individuals, neutrophils from ESKD patients migrated in significantly lower numbers
towards human IL-8 and fMLP (Figure 20C and D).
In addition, leukocytes from CKD patients have an impaired migratory capability and
respond less to inflammatory danger signals due to the uremic environment, in particular
uremic toxins43,45,214. To test whether sUA in uremic serum contributes to the intrinsic
dysfunction of neutrophils from uremic patients, neutrophils from healthy subjects were
isolated and pre-incubated with serum from either CKD and ESKD patients as well as
healthy individuals. These sera contained sUA levels as follows: CKD (7.93 ± 0.93 mg/dl),
ESKD (9.94 ± 1.3 mg/dl), and healthy (4.17 ± 0.46 mg/dl). CKD and ESKD serum decreased
the ability of healthy donor neutrophils to migrate towards IL-8 as well as fMLP compared to
neutrophils incubated with serum from healthy subjects (Figure 20E). Interestingly, this
effect was entirely reversible by pre-incubating the sera with rasburicase as indicated by an
increased number of migrating neutrophils (UA was undetectable in the serum after
rasburicase treatment) (Figure 20E). This further confirmed that HU contributed to the
impaired ability of neutrophils from uremic patients to migrate.
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Fig. 20: Uremia impairs neutrophil migration in ESKD patients. Human neutrophils were isolated
from CKD and ESKD patients as well as healthy individuals. (A to B) Expression (MFI) of CD62L
(A) and MAC-1 (B) determined by flow cytometry (healthy, n = 15; CKD, n = 10; ESKD, n = 18;
one-way ANOVA). (C to D) Number of neutrophils per µl isolated from healthy individuals and
ESKD patients that migrated though the transwell membrane towards the chemoattractants human IL-
8 (C) and fMLP (D) (healthy, n = 6-7; ESKD, n = 6; two-way ANOVA) were determined by flow
cytometry after 3 hours. (E) Healthy neutrophils were incubated with serum from healthy individuals,
CKD or ESKD patients in the absence or presence of rasburicase, and the number of neutrophils per
µl that migrated towards fMLP was determined by flow cytometry after 3 hours (n = 5-6; two-way
ANOVA). Data are mean ± SEM. * p<0.05; ** p<0.01; *** p<0.001; ns = not significant.
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4.6 Uremia does not affect MSU crystal-induced NET formation in ESKD
patients
NETs are released by neutrophils, which initially were identified as an antimicrobial, net-like
structure that consist of histone and other antimicrobial proteins215. Growing evidence imply
that NETs are also involved in sterile inflammation-related diseases, such as rheumatoid
arthritis216, atherosclerosis217, vasculitis218 and lupus219. Schauer C, et al. have previously
shown that MSU crystals can induce NET formation and NETosis as well as aggregated
NETs162. Another report showed that NET formation is increased in uremic patients220. To
investigate whether this is also the case in this patients cohort, neutrophils from healthy
volunteers and ESRD patients were stimulated with MSU crystals or phorbol myristate
acetate (PMA), as positive control221 and quantified NET formation by staining with
neutrophil elastase (NE) and cit. histone H3 antibodies. Immunofluorescence microscopy
illustrated that neutrophils from healthy volunteers and ESKD patients released significantly
more NE and cit. histone H3 (% area) upon MSU crystal or PMA stimulation compared to
untreated (medium control) (Figure 21A). However, we did not observe any difference
regarding NE or histone H3 release between healthy volunteer and ESKD patients (Figure
21A).
Furthermore, DNA-MPO and DNA release are known to predominantly be released during
NET formation222. As shown in Figure 21B and C, DNA-MPO and DNA release were
significantly increased in both MSU crystal- and PMA-stimulated healthy neutrophils
compared to unstimulated healthy neutrophils. However, stimulated neutrophils from CKD
and ESKD patients showed a trend towards more DNA-MPO and DNA release compared to
medium, but not significant. In addition, there was no significant difference in the DNA-
MPO and DNA release observed in neutrophils between CKD and ESKD patients and
healthy volunteers (Figure 21B and C). Together, the findings suggested that CKD- and
ESKD-related HU had no effect on MSU crystal and PMA-induced NET formation.
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Figure 21: Uremia does not affect MSU crystal-induced NET formation in ESKD patients.
Blood neutrophils were isolated from CKD and ESKD patients as well as healthy individuals, and
stimulated with MSU crystals or PMA or left untreated (medium) for 3 hours. (A) NETs were stained
with neutrophil elastase (NE), citrullinated histone H3 (cit. histone H3) and DAPI (for DNA release),
and the % area of cit. histone H3 and NE quantified using the software ImageJ (healthy, n = 6; ESKD,
n = 14). (B to C) Supernatants from MSU crystal- and PMA-stimulated neutrophils were collected
and the DNA and MPO release determined using a DNA-MPO ELISA kit (n = 4) (B) and the
fluorescence intensity of the dye PicoGreen (healthy, n = 8; CKD, n = 13; ESKD, n = 14) (C). Data
are mean ± SEM. * p<0.05; ** p<0.01; ns = not significant by two-way ANOVA.
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4.7 Soluble UA suppresses the monocyte function
Monocytes recruit in high numbers to the site of MSU crystal-induced inflammation (detailed
information in section 1.3.3). HU and CKD also impaired monocyte recruitment in a mouse
model of gout (section 4.2). However, previous reports demonstrated that monocytes isolated
from uremic patients are hyporesponsive to ex vivo LPS or MSU crystal stimulation,
indicating a reduced ability to synthesize pro-inflammatory cytokines33.
4.7.1 Soluble UA suppresses LPS- and MSU crystal-induced pro-inflammatory cytokine
expression in human monocytes
To examine the role of HU in this context, monocytes from CKD and ESKD patients as well
as healthy subjects were isolated by CD14+ bead separation. CD14+ monocytes were
identified as CD15-CD14+CD16- by flow cytometry (gating strategy) with a purity of 88.3%
(Figure 22A). The number of isolated CD14+ monocytes from CKD and ESKD patients as
well as healthy individuals were shown as per/ml and there was no difference between the
groups (Figure 22B).
Figure 22: No difference in number of monocytes between uremic patients and healthy controls.
(A) CD14+ monocytes were isolated (see methods and materials) and identified as CD15-
CD14+CD16- by flow cytometry (with gating strategy) with a purity of approximately 88%. (B) The
number of isolated neutrophils per ml from CKD and ESKD patients as well as healthy individuals.
Data are mean ± SEM (healthy, n = 15; CKD, n = 10; ESKD, n = 18; one-way ANOVA); ns = not
significant.
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To investigate the role of HU on the functional properties of monocytes from uremia patients,
CD14+ monocytes from healthy, CKD and ESKD patients were stimulated with LPS, MSU
crystals or medium alone. Comparing LPS-stimulated healthy monocytes with LPS-
stimulated monocytes from CKD patients, the mRNA expression levels of NLRP3, ASC,
NFκB, IL-6, TNF-alpha, and CCL2 were down-regulated but not the anti-inflammatory
cytokine IL-10 (Figure 23A). This decreased inflammatory response to LPS was more
pronounced in monocytes isolated from ESKD patients (Figure 23A). MSU crystal-
stimulated monocytes showed a similar trend in the tested gene, although not all genes were
significantly down regulated (Figure 23B).
In order to determine whether sUA accounted for the decreasing pro-inflammatory gene
expression seen in monocytes from CKD and ESKD patients, monocytes from healthy
individuals were next stimulated with LPS or MSU crystals in the presence or absence of 0.6
mM sUA. As shown in Figure 23C, the mRNA expression of NLRP3, TNF-alpha and IL-6
increased in LPS- or MSU crystal-stimulated monocytes compared to medium control.
However, sUA alone did not alter the gene expression. Interestingly, pre-incubation with 0.6
mM sUA significantly reduced the LPS- and MSU crystal-induced mRNA expression of
these pro-inflammatory mediators (Figure 23C).
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Figure 23: Soluble UA mediates the defective inflammatory function of monocytes in uremic
patients. (A to B) CD14+monocytes were isolated from CKD and ESKD patients as well as healthy
individuals, and stimulated with LPS or MSU crystals or left untreated (medium). After stimulation,
RNA expression levels of the genes NLRP3, ASC, NFKB-p50, IL-6, TNF-alpha, IL-12p40, CCL2 and
IL-10 determined via RT-PCR. Heat maps of gene expression data after LPS (A) and MSU crystal (B)
stimulation. Color intensity represents the mean log2 fold change within each row (mean expression
value of stimulated vs. medium control). P-values of genes were calculated between healthy vs. CKD
or healthy vs. ESKD of stimulated monocytes (n = 4-10 per group, Student’s t-test). (C) CD14+
monocytes isolated from healthy individuals were pre-incubated with 0.6 mM sUA prior to
stimulation with LPS or MSU crystals or left untreated (medium). After stimulation, RNA expression
levels of the genes NLRP3, TNF-alpha, and IL-6, determined via RT-PCR (n = 4-7 per group; one-
way ANOVA). Data are mean ± SEM and values are representative of two independent experiments.
* p<0.05; ** p<0.01; *** p<0.001; ns = not significant.
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4.7.2 Soluble UA suppresses intracellular cytokine expression in monocytes
The data in section 4.7.1 have shown that sUA suppressed LPS- and MSU crystal-induced
pro-inflammatory cytokines mRNA expression in human monocytes. To look whether sUA
also affected the intracellular protein levels, monocytes from healthy individuals were pre-
incubated with 0.6 mM sUA prior to stimulation with LPS or MSU crystals or left untreated
(medium) for 8 hours. After stimulation, the percentage of TNF-α+IL-6-, TNF-α-IL-6+, and
TNF-α+IL-6+ monocytes was determined by intracellular staining and quantified using flow
cytometry. Flow cytometric analysis for the intracellular cytokines IL-6 and TNF-α
confirmed that sUA significantly reduced the number of IL-6 and TNF-α single-positive as
well as of IL-6/TNF-α double-positive activated monocytes compared to LPS or MSU crystal
stimulation only, indicating that sUA suppressed the inflammatory function of monocytes
(Figure 24 A to C).
Figure 24: Soluble UA mediates the defective inflammatory function in monocytes (A to C)
CD14+ monocytes were isolated from healthy individuals, pre-incubated with 0.6 mM sUA and then
stimulated with LPS or MSU crystals or left untreated (medium) for 8 hours. After stimulation, the
percentage of TNF-α+IL-6- (A), TNF-α-IL-6+ (B), and TNF-α+IL-6+ (C) monocytes determined by
intracellular staining and quantified using flow cytometry (n = 4 per group; one-way ANOVA). Data
are mean ± SEM and values are representative of two independent experiments. * p<0.05; ** p<0.01;
*** p<0.001; ns = not significant.
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4.7.3 Soluble UA supresses PSGL-1 expression in monocytes
Monocytes migrate in lower numbers towards MSU crystal-induced inflammation under
hyperuricemic conditions (see section 4.2.1). The recruitment of circulating monocytes to the
site of inflammation requires P-selectins such as the glycoprotein ligand-1 (PSGL-1), which
is important for monocyte rolling, as well as adhesion molecules such as the very late antigen
4 (VLA-4)223,224. To test whether sUA affected monocyte recruitment by inhibiting surface
marker expression, monocytes from healthy individuals were isolated and pre-incubated with
0.6 mM sUA prior to stimulation with LPS. After stimulation, the expression of CD162
(PSGL-1) and CD49a (VLA-4a) were determined by flow cytometry. LPS stimulation
increased the expression of PSGL-1 on monocytes, whereas sUA significantly decreased
PSGL-1 expression (Figure 25A). However, LPS nor sUA had an effect on the expression
levels of VLA-4 compared to unstimulated monocytes (Figure 25B).
Figure 25: Soluble UA suppresses PSGL-1 expression in monocytes. CD14+ monocytes isolated
from healthy individuals were pre-incubated with 0.6mM sUA prior to stimulation with LPS or left
untreated (medium). Expression (MFI) of CD162 (PSGL-1) (A) and CD49a (VLA-4a) (B) determined
by flow cytometry (n = 6). Data are mean ± SEM and values are representative of two independent
experiments. * p<0.05; ** p<0.01; *** p<0.001; ns = not significant by one-way ANOVA.
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4.7.4 Soluble UA inhibits activated monocyte-induced formation of NETs
Previous studies including data within this thesis have shown that MSU crystals can directly
induce NET formation182. However, soluble mediators, including IL-1β and TNF-α, released
from activated macrophages can indirectly promote NETs release225,226. In order to
investigate whether sUA can indirectly affect NET formation via monocyte-derived soluble
mediators, healthy CD14+ monocytes were pre-treated with sUA (0.6 mM) prior to
stimulation with MSU crystals or LPS. After stimulation, supernatants from MSU crystal-
and LPS-activated monocytes were collected and added to freshly isolated neutrophils from
healthy subjects for three hours. As shown in Figure 26, soluble mediators released from
LPS- or MSU crystal-activated monocytes induced NET release, as indicated by an increase
in the % area of cit. histone H3 and NE. However, this effect was attenuated by adding
supernatants that from sUA+LPS- or sUA+MSU crystal-stimulated monocytes (Figure 26).
These data indicated that sUA suppressed the function and accordingly the release of pro-
inflammatory mediators in monocytes; therefore altering secondary effects on other immune
cells, specifically NET formation.
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Figure 26: Soluble UA inhibits the release of inflammatory cytokines by activated monocyte-
induced NET formation. Human blood CD14+ monocytes and neutrophils were isolated from
healthy individuals. CD14+ monocytes were pre-incubated with or without sUA (0.6 mM) and then
stimulated with MSU crystals or LPS or left untreated (medium). Supernatants (SN) from activated
monocytes were collected and added to the neutrophil culture for 3 hours. NETs were stained with
neutrophil elastase (NE), citrullinated histone H3 (cit. histone H3) and DAPI (for DNA release), and
the % area of cit. histone H3 and NE quantified using the software ImageJ. Data are mean ± SEM and
values are representative of two independent experiments. * p<0.05; ** p<0.01; *** p<0.001; ns = not
significant by one-way ANOVA.
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4.8 Soluble UA modulates monocyte function by intracellular uptake via
SLC2A9/GLUT9
UA does not ligate specific surface receptors but can cross cellular membranes via a number
of solute carrier (SLC) family members and multispecific ‘drug’ transporters in the kidney
and intestine, including SLC2A9/GLUT9, SLC22A12/URAT1, OAT1, OAT3, and
ABCG2227 (see introduction 1.2.2). Multiple urate transporters have been reported to be
expressed in human renal tubular cells63. Except for renal tubular cells, endothelial cells can
also take up UA via GLUT9 leading to increased ROS production228. Unlike non-immune
cells, immune cells only express GLUT9 according to the online gene atlas database.
Currently, nothing is known about the functional role of urate transporters in immune cells,
which raises the question: Does sUA enter and modulate the inflammatory function in
monocytes?
4.8.1 Soluble UA suppresses LPS- or TNF-α-induced pro-inflammatory cytokines
expression in human monocytic THP-1 cells
To explore this question, human monocytic THP-1 cells were used. THP-1 cells are a
spontaneously immortalized monocyte-like cell line, which arrived from the blood of a boy
with acute monocytic leukemia, and are widely used for investigating monocyte structure and
function in both health and disease229. First, we tested whether sUA had similar effects on the
pro-inflammatory cytokine production on THP-1 cells compared to human primary
monocytes. There was a significant decrease in the mRNA expression of the inflammatory
genes NFκBp50, ASC, NLRP3, IL-6 and TNF-alpha when LPS- or TNF-α-activated THP-1
cells were pre-incubated with 0.6 mM sUA (Figure 27A and B). These data were consistent
with the LPS-stimulated primary CD14+ monocytes from healthy individuals (see Figure 23).
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Figure 27: Soluble UA mediates the defective inflammatory function of human monocytic THP-
1 cells. Human monocytic THP-1 cells were pre-incubated with 0.6mM sUA prior to stimulation with
LPS, TNF-α or left untreated (medium) for 4 hours. After LPS (A) or TNF-α (B) stimulation, mRNA
expression levels of the inflammatory genes NFκBp50, NLRP3, ASC, IL-6 and TNF-alpha were
determined via RT-PCR and illustrated as heat map (n = 6 per group; Student’s t-test). Data are
representative of three independent experiments.
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4.8.2 THP-1 cells take up uric acid upon stimulation of LPS via GLUT9
Whether human monocytes also express GLUT9 or other UA transporters that could mediate
uptake of sUA, THP-1 cells were pre-incubated with or without 0.6 mM sUA prior to
stimulation with LPS for 4 hours, and we found that the presence of LPS significantly
reduced the extracellular sUA levels but increased the intracellular levels of sUA (Figure 28A
and B). Benzbromarone, an inhibitor of several urate transporters with uricosuric properties,
attenuated the LPS-induced intracellular uptake of sUA (Figure 28B). This implied that LPS-
induced intracellular sUA uptake in monocytes is mediated by one or several urate
transporters and monocytes require activation signals for the SLC2A9-mediated uptake of
sUA.
Renal tubular cells express a variety of urate transporters230. The expression of SLC22A6,
SLC22A9, SLC22A11, SLC22A12 and SLC22A13 mRNA levels were tested in human renal
progenitor cells by RT-PCR and they were all highly expressed. Next, to look for the
expression of these urate transporters in THP-1 cells, we carried out RT-PCR and found that
THP-1 cells only expressed SLC2A9 but not SLC22A6 (OAT1), 11 (OAT4), 12 (URAT1) and
13 (OAT10) as demonstrated in Figure 28C. However, stimulation of THP-1 cells with LPS
did not affect the mRNA expression levels of SLC2A9 in sUA-treated THP-1 cells (Figure
28D)
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Fig. 28: Monocytes require activation signals for the SLC2A9-mediated uptake of sUA. Human
monocytic THP-1 cells were pre-incubated with 0.6 mM sUA prior to stimulation with LPS or left
untreated (medium) for 4 hours. (A) Culture supernatants were collected and the UA concentrations
measured (n = 6 per group; one-way ANOVA). (B) LPS-activated THP-1 cells with or without
0.6mM sUA were digested after treatment with vehicle or benzbromarone, and the intracellular UA
concentration measured (n = 6 per group; one-way ANOVA). (C) mRNA expression of SLC2A9,
SLC22A6, SLC22A11, SLC22A12, SLC22A13 from THP-1 cells determined by RT-PCR (n = 4 per
group; one-way ANOVA). (D) mRNA expression levels of SLC2A9 from LPS-treated THP-1 cells
with the presence or without sUA determined via RT-PCR (n = 6 per group). Data are mean ± SEM
and values are representative of three independent experiments. * p<0.05; ** p<0.01; *** p<0.001; ns
= not significant by one-way ANOVA.
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4.8.3 Knockdown of SLC2A9 in monocytes reverses the effect of sUA
To confirm that the impaired monocytes function due to sUA is regulated via Glut9, we
performed knockdown experiments using SLC2A9-specific siRNA. The effective
knockdown of SLC2A9 with siRNA in LPS-stimulated and untreated THP-1 cells was
confirmed by RT-PCR for SLC2A9 as compared to siRNA control (Figure 29A). SLC2A9
silencing significantly attenuated the suppressive effect of LPS on extracellular and
intracellular sUA levels, indicating that the uptake of sUA in LPS-stimulated monocytes
occurs via the urate transporter SLC2A9 (Figure 29B and C). The same effect on
extracellular and intracellular sUA levels by THP-1 cells was observed in response to TNF-α
(Figure 29D and E).
Figure 29: Knockdown of SLC2A9 in THP-1 cells abolished the uptake of sUA. Knockdown of
SLC2A9 using specific siRNA (siRNA SLC2A9) or scrambled siRNA (siRNA control) in THP-1
cells. After transfection and LPS stimulation, relative mRNA expression levels of SLC2A9 determined
via RT-PCR (A) (n = 4-6 per group; two-way ANOVA); concentration of sUA in the supernatants (B)
and intracellular sUA levels (C) determined using an UA assay kit (n = 4-6 per group; two-way
ANOVA). (D to E) After transfection and TNF-α stimulation, concentration of sUA in the
supernatants (D) and intracellular sUA levels (E) determined using an UA assay kit (n = 4-6 per
group; two-way ANOVA). Data are mean ± SEM and values are representative of two independent
experiments. * p<0.05; ** p<0.01; *** p<0.001; ns = not significant.
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Using scambled control siRNA, the mRNA expression of the inflammatory genes NFκBp50,
IL-6, and TNF-alpha significantly decreased in LPS+sUA-stimulated THP-1 cells compared
to LPS-activated THP-1 cells alone (Figure 30 A to C). However, SLC2A9 knockdown did
not alter the inflammatory gene expression in LPS+sUA-activated THP-1 cells compared to
LPS-activated cells only (Figure 30A to C). The same effect of sUA on the inflammatory
function in monocytes was also observed in response TNF-α independent after silencing
SLC2A9 (Figure 30D and E). In summary, monocyte activation under hyperuricemic
conditions leads to SLC2A9-mediated intracellular uptake of sUA, which inhibits the
expression of pro-inflammatory cytokines.
Figure 30: Knockdown of SLC2A9 in THP-1 cells reverses sUA effect. Knockdown of SLC2A9
using specific siRNA (siRNA SLC2A9) or scrambled siRNA (siRNA control) in activated THP-1
cells. After transfection, relative mRNA expression levels of the inflammatory genes NFKB-p50 (A),
IL-6 (B) and TNF-alpha (C) or TNF-α-stimulated THP-1 cells relative mRNA expression levels of
the inflammatory genes NFκBp50 (D) and TNF-alpha (E) determined via RT-PCR (n = 5-6 per group;
two-way ANOVA). Data are mean ± SEM and values are representative of two independent
experiments. * p<0.05; ** p<0.01; *** p<0.001; ns, not significant.
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5 Discussion
5.1 Overview
There have been many studies exploring the potential causative role of UA in the association
of HU with inflammatory disease states. This thesis provides further insights into this
previously unknown function of HU involved in gout and CKD/ESKD. The aims of this
thesis were to investigate: whether HU has immunomodulatory effects on the acute
inflammatory response in vivo during experimental gouty arthritis in CKD; the effect of sUA
on blood neutrophils from healthy volunteers and CKD/ESKD patients ex vivo, e.g.
neutrophil activation and migration, as well as NET formation in response to MSU crystals;
and the immunemodulatory role of sUA on the inflammatory function of CD14+ monocytes
from healthy volunteers and CKD/ESKD patients ex vivo and on THP-1 cells in vitro.
Our in vitro and in vivo data provided evidence that sUA acts as an endogenous modulator of
innate immunity. First, sUA regulated neutrophils recruitment by β2 integrin deactivation in
sterile inflammation during CKD. Second, SLC2A9/GLUT9 facilitates the intracellular
uptake of sUA by activated monocytes, which results in a suppressed inflammatory response.
Beyond its known role as substrate for MSU crystal formation, sUA not always has adverse
effects on other diseases.
5.2 The suppressive effect of hyperuricemia on sterile inflammation
There has been substantial interest in investigating the role of sUA as an anti-oxidant. A
protective role for HU has been demonstrated in a prospective study by Lai, et al. showing
that higher UA levels are associated with lower risks of all-cause, cardiovascular and
infection-associated mortality in women treated with continuous ambulatory peritoneal
dialysis231. In vitro studies also showed that sUA can act as a potent scavenger of singlet
oxygen232 and peroxynitite233, inhibit Akt phosphorylation in endothelial cells234, reduce
intracellular ROS in cancer cell lines235, and modulate the activity of extracellular superoxide
dismutase in atherosclerotic vessels236. The results of this study now provide insight into how
HU may influence the inflammatory response in gouty arthritis.
Our data show that HU suppresses the MSU crystals-induced sterile inflammatory response.
This was supported in an in vivo mouse model of HU with and without CKD and in vitro
experiments using human blood neutrophils and monocytes. First, HU suppressed β2 integrin
activation in neutrophils and PSGL-1 expression in monocyte isolated from CKD and ESKD
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patients compared to healthy subjects; second, HU impaired the migratory ability of
leukocytes and therefore attenuated MSU crystal-induced inflammation, and even more
pronounced in mice with HU and CKD by regulating leukocyte rolling, adhesion, and
extravasation; third, sUA inhibited the inflammatory function of human monocytes in
response to inflammatory stimuli via the urate transporter Glut9, which might be a potential
mechanism for the suppressive effect of HU in ESKD patients.
In contrast to our study, many studies suggest that sUA directly contributes to oxidative stress
and inflammation. For example, sUA has been identified as a dangerous signal that can alert
the immune system to dying cells121, activate TLRs and induced pro-inflammatory cytokine
production in human peripheral blood mononuclear cells122, and initiate the AKT-PRAS40
autophagy pathway in human monocytes123, and trigger the activation of the NLRP3
inflammasome in bone marrow derived macrophages120. Apart from immune cells, sUA has
the ability to activate MAP kinase signaling in adipocytes through increased ROS production
and oxidative stress124. Soluble UA activates NFκB and MAPK signaling, cell proliferation in
vascular smooth muscle cells80,126,127, and induces endothelial dysfunction by activating the
HMGB1/RAGE signaling pathway237. Furthermore, sUA also can reduce the production of
nitric oxide (NO), a regulator molecule for cardiovascular system and hypertension238,239,
either by affecting NO biosynthesis, or by reducing NO bioavailability126,240. However,
currently, the overall functional importance of HU in vitro and in vivo remains controversial.
UA is the end product of the purine metabolism in humans beings due to the loss of the
enzyme uricase during evolution61, in addition, the continuous UA production and the
reabsorption during renal excretion together result in high serum UA level in humans62.
However, rodents have uricase, therefore it is difficult to develop a mouse model with stable
HU. Currently, most in vivo studies that investigate the function of UA are based on very low
serum UA levels (2-5 mg/dl)120,126,241–243, which would not even be considered clinically as
HU. For example, when gavaging rats with the uricase inhibitor oxonic acid, the serum UA
levels remain either below 2 mg/dl126 or rise up to 4 mg/dl241. By using an high-fat diet-
induced HU model of type 2 diabetes, rats will develop serum UA level of around 2 mg/dl243.
And even when daily intraperitoneal injected mice with UA (250 mg/kg), the serum UA
concentration will still be only around 180 µmol/l (3 mg/dl)244. GWAS found that Glut9 is a
major urate transporter in humans and mice. Humans carrying the Glut9 loss-of-function
mutation develop familial renal hypouricemia type 2, a condition characterized by
hypouricemia. In mice, serum UA levels are controlled by the hepatic breakdown and renal
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processes of reabsorption and secretion. A systemic knockout of Glut9 leads to moderate HU,
massive hyperuricosuria and an early-onset of mild renal insufficiency; while the liver-
specific inactivation of Glut9 causes severe HU and hyperuricosuria, in the absence of urate
nephropathy or any structural abnormality of the kidney207. Kidney damage and inflammation
was not observed in Alb-creERT2;Glut9lox/lox mice that only developed HU. On the other
hand, Alb-creERT2;Glut9lox/lox mice fed a high-fat diet with inosine developed kidney injury
due to the deposition of uric acid crystals. This mouse model may imply that HU itself may
not be sufficient to cause CKD. However, argument about whether HU causes CKD and
contributes to CKD progression have been a matter of debate for many years, but all clinical
studies so far cannot fully conclude whether HU is just the cause or the consequence of
CKD245. For judging the purpose of ULT in CKD patients, further studies are needed to
clarify the contribution of HU on CKD progression.
5.3 Hyperuricemia mediates neutrophil migration but not NET formation
Using an in vivo and in vitro approach, our study shows for the first time that HU directly
impairs leukocyte recruitment, specifically leukocyte rolling velocity, adhesion, and
extravasation via β2 integrin deactivation, which diminished MSU crystal-related tissue
inflammation, a model mimicking sterile inflammation in acute gouty arthritis. Meanwhile,
when HU+CKD mice were treated with rasburicase to decline the serum UA level, the
decreased neutrophils migration and reduced inflammatory cytokines were restored.
Furthermore, rasburicase treated sera from CKD/ESKD patients also restored the capability
of healthy neutrophils to migrate towards chemoattractants using transwell migration assays.
This finding may explain why the initiation of ULT can trigger a new onset of acute gouty
arthritis246. Current treatment guidelines recommend concomitant prophylaxis with
colchicine143, an inhibitor of neutrophil activation and migration247.
Neutrophils express more than 30 surface receptors that are related to multi-functions,
including G protein-coupled receptors, Fc receptors, adhesion receptors, chemokine receptors
and pattern recognition receptors248. It is well-known that neutrophils from CKD/ESKD
patients show changes in surface receptor expression leading to functional abnormalities due
to numerous metabolic waste and toxic substances. For example, accelerated neutrophil
apoptotic cell death37, reduced chemotactic activity, lower cellular phagocytic response and
reduced oxidative metabolism leading to intracellular killing40,214. CKD/ESKD patients suffer
from a high incidence of recurrent bacterial infections and inflammation35,37,249,250, which has
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been linked to an unresponsiveness of neutrophils to further stimuli, accompanied by an
impaired migratory behavior251.
Neutrophils chemotaxis is critical for appropriate recruitment to sites of inflammation.
Reports have also shown that leptin43, resistin45, modified ubiquitin42 and granulocyte
inhibitory proteins41 can contribute to a disturbed neutrophil chemotactic ability in uremic
patients. Rossaint et al. identified a role for the fibroblast growth factor 23, which is highly
elevated in uremic patients, to deactivate neutrophil integrins and thereby inhibiting
neutrophil rolling, adhesion and transmigration in infection and inflammation during
CKD250,252. Several other endogenous regulators of neutrophil integrin activation and
transmigration have been identified, including growth and differentiation factor 15 after
myocardial infarction253, developmental endothelial locus-1 during periodontitis254, and
AnnexinA1 during the pathogenesis of artherosclerosis255. In our study, neutrophils from
CKD/ESKD patients showed decreased expression of CD62L and Mac-1, both are adhesion
molecules important for leukocyte-endothelial cell interactions and slowing leukocyte
trafficking through the blood. This decreased expression of selectin and integrins on
neutrophils, as well as the impaired neutrophil recruitment is partly due to HU, and provides
further insights into the novel function of HU (Figure 31).
Neutrophils require stimulatory signaling events such as chemokines for the activation of
integrins, a process called inside-out signaling256. Once an increase in affinity or ‘activation’
has been achieved, integrins such as LFA-1 will bind firmly to the ligand and signal back into
the cell on which it is expressed. This is termed outside-in signaling, and the effector
functions of adhesion and cell migration depends on this signaling256. Besides these known
endogenous regulators, our present findings now demonstrate a previously unrecognized role
of HU on the inside-out signaling in activated neutrophils in the context of CKD-related gout
by impairing their migratory ability to the site of crystal-induced inflammation (Figure 31).
However, the exact intracellular or receptor-mediated effects of sUA on the inside-out and
outside-in signaling cascade need to be addressed in future studies.
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Figure 31: Schematic showing neutrophils recruitment from the vasculature into the inflamed
tissue is impaired in CKD/ESKD. In the healthy stage, MSU crystals trigger a joint inflammation,
which induces the release of inflammatory cytokines and chemokines, and leads to the activation of
endothelial cells to express selectins. Circulating neutrophils are captured by selectins, which is
followed by the activation of integrins from the inactive bend form to the open conformation with
high affinity. After integrin activation, neutrophils undergoing integrin-mediated crawling and finally
transmigrate to the site of inflammation. In ESKD, HU impaired neutrophil’s integrin activation,
leading to weakened adhesion ability and less transmigration into the inflamed joint/tissue, a
mechanism responsible for a diminished MSU crystal-induced inflammatory response less
inflammation. CKD, chronic kidney disease; ESKD, end-stage kidney disease; MSU, monosodium
urate; HU, hyperuricemia; GLUT9, glucose transporter 9.
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Many papers show that NETs play an important role in gout attack as mentioned in the
introduction162,257. After neutrophils recruit to the site of MSU crystals deposits, they can
release NETs. It was reported that neutrophils from gout patients spontaneously release NETs,
meanwhile NETs also can be induced by serum from gout patients when cultured with
healthy neutrophils258.These NETs can be visualized by detecting DNA, MPO and NE in the
synovium of gout patients. In our study, we found that neutrophils from CKD/ESKD patients
had no difference on NET formation compared to neutrophils from healthy individuals. This
suggested that uremic toxins do not relate to impaired NET formation. However, studies have
shown an increased NET formation in CKD patients (CKD stage G1-3)40 as well as in
hemodialysis patients which related to chronic inflammation and cardiovascular disease259.
Meanwhile, the impaired NETs degradation was reported to be associated with SLE260,
ANCA-associated vasculitis205,218 and rheumatoid arthritis216. In contrast, a recent study
showed that aggregated NETs due to a high density of neutrophils can have a positive role in
favoring the resolution of MSU crystal-induced inflammation by degrading cytokines and
chemokines, indicating a role for aggregated NETs in dampening chronic inflammation162.
5.4 Hyperuricemia mediates the inflammatory function of monocytes
Our data show that HU and CKD impair monocyte recruitment in a mouse model of gouty
arthritis and that HU also suppresses LPS- and MSU crystal-induced pro-inflammatory
cytokine expression in monocytes from CKD/ESKD patients. The suppressed function of
monocytes is consistent with previous reports demonstrating that monocytes isolated from
uremic patients are hyporesponsive to ex vivo LPS or MSU crystal stimulation, indicating a
reduced ability to synthesize pro-inflammatory cytokines33. It is also well-known that HU
seems to be associated with Parkinson’s disease because higher levels of serum UA are
related to a decreased risk of this neurogenerative disease261. On the other hand, monocytes
from Parkinson’ disease patients are hyperactive in response to LPS stimulation, and that this
hyperactivity correlates with the disease severity262. HU itself did not change gene expression
of monocytes but only suppressed the hyperactivity to a “second stimuli”, which may explain
the suppressed function of monocytes in Parkinson’s disease as well as our data in ESKD
patients.
In contrast, other studies suggest that sUA directly contributes to oxidative stress and
inflammation in monocytes. For example, sUA has been identified as a dangerous signal that
can alert the immune system to dying cells121, activate TLRs and induced pro-inflammatory
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cytokine production in human peripheral blood mononuclear cells122, and initiate the AKT-
PRAS40 autophagy pathway in human monocytes123, trigger the NLRP3 inflammasome in
bone marrow derived macrophages120. However, the overall functional importance of HU in
vitro and in vivo remains controversial due to the use of clinically irrelevant sUA
concentrations of 12 to 50 mg/dl for in vitro experiments120,123,241,243. These UA
concentrations exceed the saturation point of solubility and form microcrystals that in turn
induce the activation of the NLRP3 inflammasome and other inflammatory signaling
pathways in monocytes156,169. Further studies to investigate the mechanisms of UA’s effect on
monocyte are still needed.
The exact intracellular mechanism how sUA suppresses the inflammatory function of human
monocytes in response to LPS- or MSU crystal is not known. These intracellular processes
may occur following uptake of sUA via urate transporters63. Although many of these urate
transporters are highly expressed in the kidney and intestine, recent studies found SLC22A12
and SLC2A9 to be expressed in human endothelial cells, leukocytes and chondrocytes263–265.
The urate transporters SLC2A9 and BCRP/ABCG2234 can regulate the sUA uptake in human
umbilical vascular endothelial cells, which further triggers cell injury and inflammation.
Unlike in endothelial264, pancreatic beta86 and vascular smooth muscle cells241, our data show
that the sUA uptake by monocytes occurs via SLC2A9 leading to this suppressed monocyte
phenotype. Interestingly, this uptake only seems to happen in the presence of stimuli, such as
LPS and TNF-α, indicating that monocytes require a second signaling event for the
intracellular uptake of sUA. Whether other transporters apply to other cell types, e.g. urate
transporters or selective organic anion channels266, remain to be investigated in future studies.
Although, there was no difference in the MSU crystal-induced formation of NETs between
neutrophils from healthy individuals and ESKD patients, interesting was to observe that
soluble inflammatory mediators released from UA-treated activated monocytes induced less
NET formation. This is consistent with data showing that apart from the direct NET
formation by MSU crystals, soluble mediators, such as IL-1β and TNF-α, released from
activated macrophages can indirectly promote NET release225,226. Our data indicated that sUA
suppresses the function and accordingly the release of pro-inflammatory mediators in
monocytes; therefore altering secondary effects on other immune cells, specifically NET
formation. As shown previously, NETs can contribute to the resolution phase of an acute
gout attack162. Now, we identified another possible mechanism of shutting down sterile
inflammation showing that HU induces secondary effects on NET formation and might
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therefore explain why many patients have lower serum UA levels during an acute gout
flare189,267.
Figure 32: Schematic illustrating the immunomodulatory effects of HU on monocyte function in
sterile inflammation during CKD/ESKD. Under healthy conditions, monocytes migrate from the
blood into the inflamed joint. Once monocytes enter the inflamed joint space, they get activated by
MSU crystals leading to the release of pro-inflammatory cytokines and chemokines, characteristic
features for an acute inflammatory response. In the setting of HU and CKD/ESKD, monocytes take
up sUA via GLUT9 which results in impaired monocyte recruitment from the blood into the joint and
a suppressed GLUT9-mediated inflammatory monocyte phenotype in response to MSU crystals. CKD,
chronic kidney disease; ESKD, end-stage kidney disease; MSU, monosodium urate; HU,
hyperuricemia; GLUT9, glucose transporter 9.
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5.5 Limitations of this study
One limitation of this study is that we lack information on whether the enrolled CKD and
ESKD patients had a previous history of gouty arthritis. Only patients that did not receive
ULT or immunosuppressive drugs were included into the study. However, this does not rule
out the presence of MSU crystal deposits within the joints of CKD and ESKD patients.
Prospective studies have shown that MSU crystals can also be found in the joint space of
ESKD patients, despite the absence of active inflammatory gout attacks268. Whether the
formation of MSU crystals within joints might also be altered in ESKD patients remains
elusive.
The pathophysiology of an acute gout attack in humans is complex and to get more insights
into the cellular response one would need to retrieve synovial fluid from patients before and
after an acute gout attack has occurred. However, this is ethically not possible. Therefore,
animal models have been developed for studying gouty inflammation in more detail. The
established mouse models of gout that are widely used in the literature are: the joint model269,
the peritoneal model169 and the air pouch model162. All mouse models do have some
limitations including the small size of murine joints limits the range of investigations that can
be performed, and the absence of osteoclasts and chondrocytes in the bone niche as well as
the absence of cartilage and bone. Within this thesis, the air pouch model and the previously
unknown intravital microcopy model of the cremaster muscle were used as inflammatory
mouse models for acute gout. The air pouch model is beneficial due to the easy access to get
enough recruited leukocytes and lavage fluid to study the inflammatory response induced by
MSU crystals. In addition, using the cremaster muscle as the inflammatory model for acute
gout makes it possible for us to study and virtualize the leukocyte recruitment under the
microscope in the different stages of rolling, adhesion and transmigration. Except for the
shortages mentioned above, these two models do not include the joint structure.
THP-1 cells are a monocyte-like cell line and derived from the peripheral blood of a boy with
acute monocytic leukemia229. Using THP-1 cells for in vitro studies are widely appreciated in
the literature to investigate function of human monocytes and THP-1-differentiated
macrophages. Here, we used THP-1 cells because they are easier to obtain and to handle with
less variation in cell culture compared to human primary monocytes. These cells are also
non-adherent cells, which is convenient when performing sUA uptake experiments and
siRNA knockdown assays. However, unlike primary human blood monocytes, THP-1 cells
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only express low levels of CD14 accompanied with reduced responsiveness to LPS. It would
be still of importance to investigate the effects of sUA on human primary monocytes in the
future.
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6 Conclusions
The results provide new insights into a potential immune-suppressive function of HU. Our in
vitro and in vivo data demonstrate that sUA has immunomodulatory effects during sterile
inflammation, e.g. on the immune response induced by MSU crystals, beyond its known role
as substrate for MSU crystal formation.
The findings of the current study have multiple implications that are listed as followed and
summarized in Figure 32:
 HU contributes to CKD-related suppression of MSU crystal-induced gouty arthritis-
like sterile inflammation.
 Rasburicase treatment reversed the suppressive effect HU.
 HU and CKD attenuate MSU-crystal-induced leukocyte rolling, adhesion, and
extravasation in vivo.
 sUA regulated neutrophils recruitment by supressing β2 integrin expression and
activation in sterile inflammation during CKD.
 SLC2A9/GLUT9 facilitates the intracellular uptake of sUA by activated monocytes,
which results in a suppressed inflammatory response.
 HU does not directly affect MSU crystal-induced NET formation in ESKD patients,
but indirectly though soluble mediators released form suppressed monocyte.
Taken together, our research provides new insights on the immunomodulatory effects of HU
and gives possible clinical explanations for the unexpectedly low incidence of acute gouty
arthritis in CKD/ESKD patients as well as the increased risk for acute gout attacks in patients
upon starting ULT, highlighting that soluble and crystalline UA have opposite effects on
innate immunity.
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Figure 33: Schematic illustrating the immunomodulatory effects of HU on neutrophil migration
and monocyte function in sterile inflammation during ESKD.
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7 Future directions in the context of hyperuricemia
Integrin signaling through the leukocyte membrane is bidirectional, known as “inside-out”
and “outside-in” signaling, which mediates cell migration and activation. Our present
findings now demonstrate a previously unrecognized role of HU on neutrophil recruitment by
inhibiting β2 integrin activation (“inside-out” signaling) in sterile inflammation during CKD.
Future experiments are needed to also investigate the exact intracellular or receptor-mediated
effects of sUA on the outside-in signaling cascade to clarify the mechanism.
Our in vitro study shows SLC2A9/GLUT9 facilitates the intracellular uptake of sUA in LPS
and TNF-α-activated monocytes, which results in a suppressed inflammatory response.
Currently it is not known how exactly GLUT9 mediates intracellular sUA uptake and which
downstream signaling events other than TNF-α, IL-6, NFκB and the NLRP3 inflammasome
are involved in inhibiting activated monocytes. We found that human monocytes only
express GLUT9 but not the previously reported urate transporters in tubular cells, including
OAT1, OAT4, OAT12 URAT1 and OAT10. Future studies could be undertaken to determine
whether membrane channels that mediate the sUA transport in activated monocytes are
involved.
We have identified sUA as an endogenous modulator of innate immunity, especially
neutrophils and monocytes. Whether HU can directly affect other cell types in the context of
gouty arthritis is currently not known. For example, endothelial cells are important for the
transmigration of neutrophils and monocytes and are in direct contact via adhesion molecules.
It is known that CKD patients suffer from endothelial cells dysfunction270. However, whether
this is due to HU and contributes to the impaired neutrophil recruitment still needs to be
investigated.
Besides the immunosuppressive role of HU in sterile inflammation, it would be of interest to
investigate whether HU can modulate the immune response during infection. CKD/ESKD
patients suffer from a high incidence of recurrent bacterial infections and inflammation,
which has been linked to an unresponsiveness of neutrophils to further stimuli, accompanied
by an impaired migratory behavior.
The findings reported in this thesis are vital for advocacy among doctors and researchers to
help patients to improve the treatment of gout care, especially patients with CKD and ESKD.
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It is tempting to speculate on a role of HU also in CKD/ESKD-related secondary
immunodeficiency and that correcting HU in CKD/ESKD may restore host defense. This
remains to be addressed in future experiments. Furthermore, more nationwide clinical studies
and patients registries are needed in order to predict the burden of gouty arthritis in the
general population of individuals with HU as well as in ESKD patients stage G5D.
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10 Appendix
Composition of buffers used in this thesis
PBS buffer:
NaCl 8 g
Na2HPO4 1.16 g
KH2PO4 0.2 g
KCl 0.2 g
Dissolved in 1l ddH2O and adjust pH to 7.4 with HCl.
0.1M Sodium Carbonate buffer:
NaHCO3 1.426 g
Na2CO3 0.318 g
Dissolved in 0.2 l ddH2O and adjust pH to 9.5 with NaOH.
Red Blood Cell lysis buffer
NH4Cl 0.829 g
NaHCO3 0.1 g
EDTA 0.037 g
Dissolved in 100 ml ddH2O, filtered with 0.2m filter and storage at 4 °C.
FACS buffer :
D-PBS 500 ml
NaN3 0.05 g (0.01 %)
BSA 0.5 g (0.1 %)
Storage at 4 °C.
0.01% Tamoxifen:
Tamoxifen 15 mg
100% Ethnol 0.15 ml
Sunflower oil 1.35 ml
Prepare freshly and preheated in 37 °C water bath to dissolve the power.
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Magnetic separation buffer :
D-PBS 100 ml
0.5M EDTA 0.4 ml
BSA 0.5 g
Filtered with 0.2m filter and storage at 4 °C.
Collagenase / DNAse solution:
Collagenase 10 mg
1mg/ml DNAse 0.2 ml
HBSS 9.8 ml
Always prepare freshly.
